FEATURING:

Premium Exhibits
Visit exhibits from industry, health information technology companies, NCCN Member Institutions, and more.

General Poster Sessions I & II
Posters will be presented during breakfast, lunch, and breaks on Friday and Saturday.

Poster Tours
12:30 PM | Friday and Saturday
Experts will lead guided tours of the posters and discuss research highlights.

NEW First Timers Breakfast
7:30 – 8:30 AM | Friday
First-time conference attendees can enjoy giveaways, enter to win prizes, and meet with NCCN staff and leaders. Return attendees are also welcome!

NEW Headshot Station | Booth #628
12:00 – 3:30 PM | Friday and Saturday
Smile! Stop by to have your headshot taken by a professional photographer. Photos will be taken on a first-come, first-served basis.

Reimbursement Resource Room
Connect with organizations about patient support resources and services to mitigate reimbursement challenges.

Patient Advocacy Pavilion
Visit patient advocacy kiosks representing a range of disease types and learn about resources for patients.

Visit NCCN Booth #624 and NCCN Foundation Booth #622
• Learn about NCCN resources for clinicians and patients.
• Drop off completed Poster Session Form(s) to enter to win an Amazon Echo Show 5.
• Visit at least six booths and drop off a completed Exhibitor Passport form to receive a free prize while supplies last.
• Complete the NCCN Trends™ Survey to enter to win Beats Studio Buds.

Product Theaters
Magnolia 7, 8, 9
Hear about new products and programs in oncology.
At Eisai, everything we do is guided by a simple principle: patients and their families come first. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. **We call this human health care or hhc**, giving first thoughts to patients and their families and helping increase the benefits health care provides.

**Our hhc mission** is what drives us to discover innovative solutions and therapies that help address unmet needs within the communities that we seek to serve.

*Eisai is proud to support the National Comprehensive Cancer Network.*

**hhc**

*human health care*
Commercial Sponsors

Platinum

Eisai
Incyte Corporation

Gold

Johnson & Johnson
Regeneron

Silver

AstraZeneca

Bronze

BeiGene
GSK
Jazz Pharmaceuticals
Servier Pharmaceuticals
Watch KOL expert series at darzalexhcp.com
Visit the AstraZeneca Booth at NCCN 2024!

For more information, please visit us at www.astrazeneca-us.com

Lynparza®
olaparib tablets

Truqap™
capivasertib
160 mg • 200 mg tablets

ENHERTU™
Trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Please scan for complete Prescribing Information, including Boxed WARNINGS, and Medication Guide, or visit www.ENHERTU.com

CALQUENCE®, IMFINZI, IMJUDO, LYNPARZA and TAGRISSO are registered trademarks, and TRUQAP is a trademark of the AstraZeneca group of companies.

©2024 AstraZeneca. All rights reserved. US-84711   Last Updated 02/24

FREE for your mobile device

Virtual Library of NCCN Guidelines App

• Easy access to NCCN Guidelines®, global resources, and NCCN Guidelines for Patients®
• Hyperlinks within the Guidelines
• Ability to quickly share Guidelines
• Optimized search and viewing options

Download today! NCCN.org/apps
At Johnson & Johnson, we are working on developing treatments that work with the natural defenses of the body in order to halt the growth of cancers such as multiple myeloma. Everything we do gets us closer to a future where cancer is a thing of the past.
STAY UP TO DATE WITH THE DATA

DARZALEX Faspro®
(daratumumab and hyaluronidase-fihi)
Injection for subcutaneous use | 1,800mg/30,000 units

See more at DARZALEXHCP.com
### EXHIBITORS

<table>
<thead>
<tr>
<th>Company/Group</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acrotech Biopharma, Inc.</td>
<td>601</td>
</tr>
<tr>
<td>Astellas</td>
<td>700</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>803</td>
</tr>
<tr>
<td>BeiGene</td>
<td>716</td>
</tr>
<tr>
<td>CVS Specialty</td>
<td>617</td>
</tr>
<tr>
<td>Daichi Sankyo, Inc.</td>
<td>606</td>
</tr>
<tr>
<td>ECG Management Consultants</td>
<td>602</td>
</tr>
<tr>
<td>Eisai</td>
<td>701</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>822</td>
</tr>
<tr>
<td>EMD Serono</td>
<td>620</td>
</tr>
<tr>
<td>Fennec Pharmaceuticals</td>
<td>709</td>
</tr>
<tr>
<td>Foundation Medicine</td>
<td>900</td>
</tr>
<tr>
<td>Genmab</td>
<td>904</td>
</tr>
<tr>
<td>Geron</td>
<td>916</td>
</tr>
<tr>
<td>Incyte</td>
<td>703</td>
</tr>
<tr>
<td>InformedDNA</td>
<td>924</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>902</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>723</td>
</tr>
<tr>
<td>Karyopharm Therapeutics, Inc.</td>
<td>600</td>
</tr>
<tr>
<td>Kite, A Gilead Company</td>
<td>604</td>
</tr>
<tr>
<td>La Roche-Posay a L'Oreal company</td>
<td>621</td>
</tr>
<tr>
<td>LeanTaaS</td>
<td>819</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>808</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation – Commercial</td>
<td>607</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation – Medical</td>
<td>708</td>
</tr>
<tr>
<td>ONCOassist</td>
<td>926</td>
</tr>
<tr>
<td>Oncology Nutrition - Registered Dietitians / Nutritionist</td>
<td>824</td>
</tr>
<tr>
<td>OneOme</td>
<td>922</td>
</tr>
<tr>
<td>Oxford BioDynamics</td>
<td>603</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
<td>823</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>605</td>
</tr>
<tr>
<td>PreciseDX</td>
<td>704</td>
</tr>
<tr>
<td>Regeneron</td>
<td>800</td>
</tr>
<tr>
<td>Servier Pharmaceuticals</td>
<td>718</td>
</tr>
<tr>
<td>SkinCure Oncology</td>
<td>722</td>
</tr>
<tr>
<td>Stemline, a Menarini Group Company – Commercial</td>
<td>801</td>
</tr>
<tr>
<td>Stemline, a Menarini Group Company – Medical</td>
<td>711</td>
</tr>
<tr>
<td>Sun Pharma</td>
<td>707</td>
</tr>
<tr>
<td>Taiho Oncology</td>
<td>817</td>
</tr>
</tbody>
</table>

### NCCN MEMBER INSTITUTIONS

<table>
<thead>
<tr>
<th>Institution</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayo Clinic</td>
<td>724</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>623</td>
</tr>
<tr>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>625</td>
</tr>
</tbody>
</table>

### REIMBURSEMENT RESOURCE ROOM

<table>
<thead>
<tr>
<th>Company/Group</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astellas</td>
<td>R-4</td>
</tr>
<tr>
<td>BeiGene</td>
<td>R-1</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>R-3</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals</td>
<td>R-2</td>
</tr>
</tbody>
</table>

### PATIENT ADVOCACY PAVILION

<table>
<thead>
<tr>
<th>Group</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Association of Cancer Care Centers (ACCC)</td>
<td>A14</td>
</tr>
</tbody>
</table>

---

### Registration & General Session

- **Bladder Cancer Advocacy**
- **Network (BCAN)**
- **Cholangiocarcinoma Foundation**
- **Crossroads4Hope**
- **Global Colon Cancer Association**
- **GO2 for Lung Cancer**
- **Head and Neck Cancer Alliance**
- **Imersman Angels**
- **The Leukemia & Lymphoma Society**
- **LiveLung**
- **Say YES to Hope**
- **Sharsheret**
- **Tigerlily Foundation**

---

### General Session

- **Triage Cancer**
- **Veterans Prostate Cancer Awareness, Inc.**
- **Young Adult Survivors United (YASU)**

### JNCCN PUBLISHER

- **Harborside-BroadcastMed**

### NCCN

- **NCCN Foundation**
- **NCCN General Information**
- **Headshot Station**
Non-CE Product Theaters

These non-CE presentations can be viewed on the Virtual Event Platform. Attendees can also view in-person in Magnolia 7, 8, 9. No pre-registration is required.

Friday, April 5
7:50 – 8:20 AM
Key Considerations When Choosing a First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
Presented by AstraZeneca

12:00 – 12:30 PM
The Era of Multi-cancer Early Detection Testing: A Paradigm Shift in Cancer Screening
Presented by Exact Sciences Corporation

12:35 – 1:05 PM
Matters of the Heart: Diagnosing and Treating Light-Chain Amyloidosis (AL)
Sponsored by Alexion, AstraZeneca Rare Disease

Saturday, April 6
7:50 – 8:20 AM
NCCN Foundation: Empowering Patients and Research Innovation

12:00 – 12:30 PM
Understanding the Role of Advanced Practice Providers in the Management of Low-risk Myelodysplastic Syndromes (MDS)
Presented by Bristol Myers Squibb

12:35 – 1:05 PM
Expanding Options for Patients with HER2-Low mBC
Presented by Daiichi Sankyo, Inc. and AstraZeneca

Patient Advocacy Pavilion Sponsors

Emerald
AstraZeneca
BeiGene
Coherus
Eisai
Incyte Corporation
Johnson & Johnson

Topaz
AbbVie
Cencora
GSK
Lantheus
My fellow colleagues,

In patients with polycythemia vera (PV), the threat of thrombosis is real, and it is within our power to reduce it. Studies have demonstrated that elevated Hct increases a patient’s thrombotic risk. As shown in the graph below from the CYTO-PV study, the rate of CV death and major thrombosis was 4 times as high among patients whose Hct was maintained between 45% and 50% compared with those whose Hct was maintained strictly below 45%.

One of the main goals of treatment for our PV patients should be to maintain strict Hct control. From my clinical perspective, it’s important for my high-risk PV patients to remain below that 45% threshold, ideally without any need for phlebotomy. It’s a red flag to me when my high-risk patients on HU still need 3 or more phlebotomies a year. Frequent phlebotomies in patients on cytoreductive therapy signal a need to optimize treatment.

The CYTO-PV study has substantially informed the way I manage my PV patients. These data challenge the notion that PV is a cancer with a benign course.

Prithviraj Bose

*Multicenter, randomized, and controlled trial that assessed the benefit-risk profile of cytoreductive therapy with PBT or HU aimed at maintaining Hct at <45% vs maintaining Hct at 45% to 50% in 365 adult patients with PV. The composite primary endpoint was the time until cardiovascular death or major thrombosis.

†A significant increase in the risk of cardiovascular death and major thrombosis was demonstrated with Hct levels between 45% and 50% compared with Hct levels <45% (HR, 3.91; 95% CI, 1.45-10.53; *P*=0.007).

CI=confidence interval; CV=cardiovascular; CYTO-PV=Cytoreductive Therapy in Polycythemia Vera; Hct=hematocrit; HR=hazard ratio; HU=hydroxyurea; PBT=phlebotomy.


Incyte and the Incyte logo are registered trademarks of Incyte.

© 2023, Incyte. MAT-HEM-03189 02/23
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development.

Learn more at www.regeneron.com
EVEN MORE PATIENTS MAY BE RIGHT FOR BRUKINSA

REVIEW THE TRIALS SUPPORTING THE LATEST APPROVAL
For the treatment of newly diagnosed, IC-ineligible acute myeloid leukemia (AML)

COULD WAITING FOR TEST RESULTS GIVE YOUR PATIENT'S MORE TIME?

Does molecular profiling help drive your treatment selection in newly diagnosed AML? It should. Mutated IDH1 (mIDH1) is an oncogenic driver in up to 10% of AML cases. More importantly, mIDH1 is an actionable target for treatment. That’s why both the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the ASH-CAP Guidelines recommend performing molecular and cytogenetic analyses to identify IDH1 mutations in patients with AML. Further, the NCCN Guidelines® recommend expediting these analyses.

So the next time you have a patient with newly diagnosed, IC-ineligible AML, test for IDH1 mutation status BEFORE choosing treatment—your first step to treatment selection could be your patient’s first step to better outcomes.

Learn more at AMLTreatmentOption.com

Together with GSK Oncology offers a variety of access and reimbursement services in one location for all GSK oncology products.

**Reimbursement support**

- Insurance benefits investigation
- Information about prior authorizations
- Guidance on insurance denials or coverage requirements
- Coding and claims assistance for products and related services

*Together with GSK Oncology does not guarantee coverage or payer reimbursement for product treatment or administration. Healthcare professionals should confirm information directly with payers.*

**Access assistance**

- Co-pay assistance for eligible commercially insured patients
- Patient assistance program that makes free product available to eligible patients
- Information about alternative funding sources

For program terms and eligibility and to obtain a *Together with GSK Oncology* Enrollment Form, visit [TogetherwithGSKOncology.com](http://TogetherwithGSKOncology.com) or call 1-844-4GSK-ONC (1-844-447-5662), Monday-Friday, (8AM to 8PM ET)
Acrotech Biopharma, Inc.  Booth #601
Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.

Astellas  Booth #700
Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

AstraZeneca  Booth #803
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.

BeiGene  Booth #716
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing, and Cambridge, U.S.

CVS Specialty  Booth #617
Personalized Specialty Pharmacy Services
Our commitment to helping patients and their physicians manage complex drug therapies by delivering individualized patient care with compassion and dedication has made us one of the leading specialty pharmacies in the country. To learn more or to enroll patients, call 1-800-238-7828.

Daiichi Sankyo, Inc.  Booth #606
ECG Management Consultants  Booth #602
With knowledge and expertise built over the course of 50-plus years, ECG is a national consulting firm that is redefining healthcare together with its clients. ECG offers a broad range of strategic, financial, operational, and technology-related consulting services. ECG is an industry leader, offering specialized expertise to hospitals, health systems, medical groups, academic medical centers, children’s hospitals, ambulatory surgery centers, investors, and payers/health plans. As an affiliated partner of Siemens Healthineers, ECG's subject matter experts have a proven track record of delivering results fueled by top talent and technology.

Eisai  Booth #701
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families and help to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

Eli Lilly and Company  Booth #822
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

EMD Serono  Booth #620
EMD Serono is a science-led organization of curious minds dedicated to delivering transformative medicines that can make a difference in the lives of people affected by cancer.

We apply our scientific curiosity to tackling challenging tumor types in key areas—gastrointestinal (GI), genitourinary (GU), and thoracic cancers—where there are unmet needs and where we believe we can drive transformation of patient care.
About Our Exhibitors

By relentlessly pursuing potential solutions to even the most complex cancers, we hope to illuminate a path to scientific breakthroughs that impact patient care.

**Fennec Pharmaceuticals**  
Booth #709

Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.

**Foundation Medicine**  
Booth #900

*Your Essential Partner in Cancer Care*

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action to transform cancer care.

**Genmab**  
Booth #904

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. To help develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. Visit us at Genmab.com or Twitter.com/Genmab.

**Geron**  
Booth #916

Geron is a late-stage clinical biopharmaceutical company focused on development and commercialization of therapies in hematologic malignancies. We are committed to pursuing discoveries with the potential to extend and enrich the lives of patients.

**Harborside-BroadcastMed**  
Booth #619

Harborside, a division of BroadcastMed, is a leader in medical publishing and communications and a destination that has earned the trust of doctors, advanced practitioners, medical societies, medical affairs professionals, and health-care marketers. Its mission is to advance the field of oncology through better information. Its reputation for high-quality, diverse offerings and partnerships with ASCO, NCCN, APSHO, and other organizations, has led to an unmatched level of trust from clinicians.

**Incyte**  
Booth #703

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. For additional information on Incyte, please visit incyte.com and follow @Incyte.

**InformedDNA**  
Booth #924

Established in 2007 as the nation’s pioneer telehealth Genetic Counseling company, InformedDNA is an unrivaled leader in genetic counseling with a force of fully licensed, board-certified genetics experts that cover all subspecialties. We consistently earn market-leading Net Promoter Scores >75 and Provider Satisfaction Scores over 95%. Through innovative solutions that revolutionize the application of genomic insights, we enhance patient care, improve outcomes for all, and shape the future of precision health. InformedDNA is headquartered in St. Petersburg, FL. Learn more about the benefits of partnering with InformedDNA at InformedDNA.com

**Jazz Pharmaceuticals**  
Booth #902

Jazz Pharmaceuticals is focused on developing life-changing medicines for people with serious diseases with limited or no options, to allow patients to live their lives fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people the opportunity to redefine what’s possible – to make the “small wins” big again.

We are a global biopharmaceutical company with a diverse portfolio of products for adults and children, with expertise in two key therapeutic areas: neuroscience and oncology. In oncology, we investigate medicines for hard-to-treat cancers with the purpose of transforming the lives of patients and their families.

**Johnson & Johnson**  
Booth #723

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact...
See the latest data for SARCLISA + Kd

Explore the full results of the IKEMA phase 3 trial at sarclisahcp.com

Kd=Kyprolis (carfilzomib) and dexamethasone
Now in our 19th year, the Bladder Cancer Advocacy Network has committed more than $10 million in research funding to end bladder cancer. And we’re just getting started.

www.BCAN.org

Empower your patients.

Too many CLL patients are navigating their disease alone.

Please consider connecting your patients with the vital support, education, and other valuable resources that CLL Society can offer as the world’s leading authority on chronic lymphocytic leukemia.

About Our Exhibitors

health for humanity. Learn more at www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine. Follow us at @JanssenUS and @JNJInnovMed.

Karyopharm Therapeutics, Inc.  Booth #600

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering novel first-in-class cancer therapies and dedicated to the discovery, development, and commercialization of drugs to treat cancer. We believe in the extraordinary – in the dedication to positively impact patient lives and treat cancer. We are recognized leaders in XPO1 inhibition, which has the potential to engage the cell's innate ability to fight cancer. Patients embody extraordinary and deserve the same from those in their communities. That is why we choose to spend our time where it has the most significant impact: Multiple Myeloma, Endometrial Cancer, Myelofibrosis, and Diffuse Large B-Cell Lymphoma.

Kite, A Gilead Company  Booth #604

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing. For more information on Kite, please visit www.kitepharma.com.

La Roche-Posay a L’OREAL Company  Booth #621

Company Description: We are committed to providing educational resources for patients and their caregivers throughout the cancer journey. Recommended by 90,000 dermatologists worldwide, we partner with dermatologists to stay at the forefront of skincare science, pioneering cutting-edge topics like skin's microbiome. With over 750+ studies and 25 years of extensive research, we are committed to developing safe and effective products that are dermatologist developed and tested.

LeanTaaS  Booth #819

LeanTaaS is the leading provider of AI-powered and cloud-based capacity management, staffing, and patient flow software for health systems. Our iQueue products for operating rooms, infusion centers, and inpatient units are trusted by 1,000+ hospitals and centers across 185 health systems. Our solutions use Lean principles and AI/ML predictive and prescriptive analytics to forecast future demand based on historical data, recent pattern shifts, and real-time insights. They help staff and providers act quickly, confidently, and decisively to avoid operational bottlenecks before they even happen.

Merck & Co., Inc.  Booth #808

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Novartis Pharmaceuticals Corporation  Booth #607 & #708

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

ONCOassist  Booth #926

ONCOassist is a comprehensive suite of decision support tools developed by oncology professionals, for oncology professionals. It includes a range of breakthrough tools designed to manage patient care effectively.

Oncology Nutrition – Registered Dieticians/Nutritionist  Booth #824

Oncology Nutrition Dietetic Practice Group (ON-DPG) of the Academy of Nutrition and Dietetics (AND) fosters excellence in oncology nutrition via an evidence-based nutrition care process. The ON-DPG also promotes education, research and advocacy through publications, symposiums, and webinars. Attendees will gain education materials on nutrition screening and malnutrition diagnosing as up to 80% of cancer patients become malnourished during their cancer continuum. The ON-DPG endorses the vital role of a Registered Dietitian Nutritionist (RDN) as the nutrition expert on the multidisciplinary care team.

OneOme  Booth #922

OneOme – cofounded by the Mayo Clinic – is a leader in precision medicine, providing pharmacogenomic
solutions, population-level value-based care analyses and clinical decision support solutions. OneOme aims to impact patient safety, reduce the overall cost of care, and improve patient health outcomes. OneOme recently introduced RightMed for Oncology, a first-of-its-kind germline pharmacogenomics panel focused on medications used as chemotherapy and supportive care. This compliments single and double-gene tests for oncology practices, including a DPYD test covering variants *2A, *13, HapB3, c.2846A>T, & c.557A>G. [www.oneome.com](http://www.oneome.com)

**Oxford BioDynamics**  
Booth #603

Oxford Biodynamics, Plc (AIM:OBD) is a global biotech company advancing personalized healthcare by developing & commercializing precision medicine tests for life-changing diseases. Our portfolio of clinical tests and research tools based on EpiSwitch® technology aims to help physicians better understand their patient’s clinical status for therapeutic response, disease prognostication, and early cancer detection. Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments. PSE predicts a patient’s current likelihood of having prostate cancer with 94% accuracy.

**Pfizer Oncology**  
Booth #823

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients’ lives.

**PharmaEssentia**  
Booth #605

PharmaEssentia, based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our [www.pharmaessentia.com](http://www.pharmaessentia.com) to learn more.

**PreciseDx**  
Booth #704

PreciseDx is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. PreciseBreast™ is an in vitro test for early-stage breast cancer that calculates a composite risk of recurrence score based on a proprietary algorithm. PreciseBreast™ leverages AI technology within our Morphology Feature Array® to evaluate the recurrence risk of early-stage breast cancer much faster than traditional testing and with greater reproducibility and precision than any other technology currently utilized in cancer care. PreciseBreast™ is performed on digital scans without the need for tissue specimen or wet lab and can also use traditional H&E-stained slides.

**Regeneron**  
Booth #800

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center. Visit [www.Regeneron.com](http://www.Regeneron.com) to learn more.

**Servier Pharmaceuticals**  
Booth #718

Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets.

As a leader in oncology, Servier has significantly accelerated its investment in difficult and hard-to-treat cancers, with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need throughout oncology with the potential to change the lives of the patients it serves. Within these areas, Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH1 inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition.

**SkinCure Oncology**  
Booth #722

GOLD

BRONZE
About Our Exhibitors

**Spectrum Pharmaceuticals**  
Spectrum Pharmaceuticals, Inc., a subsidiary of Assertio Holdings, Inc., is a leading commercial pharmaceutical company bringing differentiated products to patients. We have a robust portfolio of branded prescription medications. The company has grown through business development including acquisitions, licensing, and mergers. To learn more, visit [www.assertiotx.com](http://www.assertiotx.com).

**Stemline a Menarini Group Company**  
Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.

**Sun Pharma**  
Sun Pharma is the world’s fourth largest specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. and Global Emerging Markets. Sun's high-growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations.

**Taiho Oncology**  
Taiho Oncology specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in preclinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada.

---

**Is Roswell Park the right one for you?**

JOIN AN ELITE, MISSION-DRIVEN TEAM WHERE YOUR IMPACT MATTERS.

**ROSWELL PARK HAS IMMEDIATE OPENINGS FOR THE FOLLOWING POSITIONS**

- Chief Pharmacy Officer & Senior Executive Director
- Director of Breast Imaging
- Chief of Nuclear Medicine & Theranostics
- Veterinary Research Pathologist
- Assistant Professor of Oncology – Leukemia
- Sarcoma Oncology, Assistant to Full Professor
- Palliative Care Physician

"I looked for a cancer center with world-class facilities and resources, where they design clinical trials and prioritize immunotherapy research. I intend to make Roswell Park a world leader in innovative cellular therapy.”

– Renier Brentjens, MD, PhD
Deputy Director and Chair, Department of Medicine

**Buffalo, New York**

[APPLY TODAY](https://RoswellPark.org/FacultyRecruitment)
Now Enrolling

A clinical trial for patients with previously treated ER-positive, HER-negative advanced breast cancer

The VERITAC-2 study is a global, phase 3, randomized open-label study of vepegestrant (ARV-471) vs fulvestrant in patients with ER+ HER2- advanced breast cancer. Vepdegestrant is a potent, selective, orally bioavailable PROteolysis Targeting Chimeric (PROTAC) small molecule that induces degradation of the ER.

Key Eligibility Criteria

- Women or men with ER-positive, HER-negative advanced breast cancer
- Progression on 1-2 lines of endocrine therapy (ET), one of which had to have been in combination with a CDK4/6i
- Duration of most recent ET of ≥6 months prior to progression
- No prior chemotherapy in advanced/metastatic setting

Primary Endpoint

- Progression-free survival by blinded independent central review

Scan here to find a clinical trial site near you.

NCT05654623
Shared knowledge creates global solutions

Your voice matters

Take the survey

Learn more at project528.youngsurvival.org | Email: project528@youngsurvival.org

FORCE improves the lives of millions of individuals and families facing hereditary breast, ovarian, pancreatic, prostate, colorectal and endometrial cancers. Our community includes people with a personal or family history of cancer, Lynch syndrome, a BRCA1, BRCA2, ATM, PALB2, CHEK2, PTEN or other inherited gene mutation linked to cancer. We accomplish this through our education, support, advocacy and research efforts.

We are grateful for the important work that you do to help members of the hereditary cancer community make informed decisions about their health. Together, we will ensure that no one faces hereditary cancer alone.
Advanced Breast Cancer (ABC) knows no boundaries, affecting individuals from diverse backgrounds, all over the world. At ABC Global Alliance, we are fostering an inclusive environment where people from different countries and backgrounds can come together, collaborate, and share knowledge and resources to improve and extend the lives of ABC patients worldwide.

The ABC Global Alliance is a non-profit association, a multi-stakeholder platform for all those interested in collaborating on common projects related to Advanced Breast Cancer.

Explore more:
www.abcglobalalliance.org
info@abcglobalalliance.org

@ABCGlobalAll @ABC-Global-Alliance

HealthTree Foundation

Leading patients to become active contributors in driving cures for incurable diseases.

- Lifetime personalized support and education
- Meaningful patient-to-patient connections
- Powerful patient data portal

Visit healthtree.org today!
Helping People Find Their Cancer Confidant

My situation felt so unique and I couldn’t help but feel so alone. But when I discovered this program, I knew I wasn’t. I’m truly blessed I found Imerman Angels.

Collaboration Opportunities
Imerman Angels is always looking to partner with organizations and groups to continue the fight against cancer, including:
- Hospital & Healthcare Professionals
- Pharmaceutical Companies
- Cancer Partner Organizations
- Academic & Research Organizations
- Employee-Benefit Programs

My situation felt so unique and I couldn’t help but feel so alone. But when I discovered this program, I knew I wasn’t. I’m truly blessed I found Imerman Angels.

2001 N. Halsted, Ste. 302, Chicago, IL 60614 • 866-IMERMAN (463-7626) • info@imermanangels.org • imermanangels.org

BEE the change!

The World of Advanced Cancer is in OUR Hands

877-937-7478
www.sayyestohope.org
Moffitt Cancer Center  Booth #623

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 56 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 9,000 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org and follow the momentum on Facebook, Twitter, Instagram and YouTube.

Roswell Park Comprehensive Cancer Center  Booth #625

Founded in 1898 and operating from a 29-acre campus on the Buffalo Niagara Medical Campus near downtown Buffalo, New York, Roswell Park today remains the only comprehensive cancer center designated by the NCI in Upstate NY. In the past year, Roswell Park’s team of 4,188 total employees, including 364 faculty members and 855 nurses, cared for more than 46,000 patients. Roswell Park helps set international standards in cancer care through its role as a founding member of the National Comprehensive Cancer Network, and consistently earns patient-satisfaction scores that are among the highest in the country.

Changing the way cancer is treated.

Kite’s singular focus is cell therapy to treat and potentially cure cancer.

We proudly serve patients around the globe from our manufacturing facilities in California, Maryland and the Netherlands.
Anal Cancer Foundation  virtual only
The Anal Cancer Foundation is dedicated to empowering anal cancer patients and accelerating prevention and treatment methods that eliminate anal cancer and HPV.

Our mission is to:

- Highlight the relevance of HPV in contracting cancer
- Accelerate a cure for the 5% of all cancers, including anal cancer, caused by HPV
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination
- Support anal cancer survivors, caregivers, scientists, and providers

Association of Cancer Care Centers (ACCC) Kiosk #A14
The Association of Cancer Care Centers (ACCC) provides education and advocacy for the cancer care community. Founded in 1974, ACCC is a powerful network of more than 40,000 multidisciplinary practitioners from over 1,700 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org. Follow us on LinkedIn; read our blog, ACCCBuzz; tune in to our CANCER BUZZ podcast; and view our CANCER BUZZ TV channel.

Bag It virtual only
Bag It educates, supports and empowers patients, caregivers & advocates. The Bag It Bag is the most respected and comprehensive resource for patient education. The Bag has a binder and resources to help patients organize medical records, cope with a diagnosis and advocate for their best quality of care. It includes publications and customizable tools designed to ensure your patients have access to current, credible information and tools to help them navigate their cancer journey.

Bladder Cancer Advocacy Network (BCAN) Kiosk #A5
The Bladder Cancer Advocacy Network (BCAN) is a community of patients, caregivers, survivors, advocates, medical and research professionals united in support of people impacted by bladder cancer. Founded in 2005, BCAN is the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease. BCAN's mission is to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community.

Visit bcan.org or email us at info@bcan.org to learn more about bladder cancer, find free resources, and/or sign up to receive our newsletter.

Cancer Support Community virtual only
The Cancer Support Community is a global nonprofit that uplifts and strengthens people impacted by cancer. We are dedicated to fostering a community where people find connection, compassion, and knowledge. We provide professionally led support and navigation services, along with social connections and award-winning education—when, where, and how impacted individuals prefer throughout their cancer experience. We break down barriers to care through education, research, and advocacy. www.cancersupportcommunity.org

Cholangiocarcinoma Foundation Kiosk #A11
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c)(3) nonprofit organization. Its mission is to find a cure and improve the quality of life for cholangiocarcinoma patients. The Foundation is also part of a global alliance and partners with institutions in the United Kingdom, Thailand, Italy, Denmark, Japan, and other countries.

CLL Society virtual only
CLL Society is an inclusive, patient-centric, physician-curated nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) community through patient education, advocacy, support, and research. We explain the rapidly changing therapeutic landscape and the importance of clinical trials, build patient support networks, engage in research, and educate providers and patients. We believe SMART PATIENTS GET SMART CARE™. Learn more at cllsociety.org.

Crossroads4Hope Mission:  Crossroads4Hope's network embraces all people touched by cancer—the diagnosed and their loved ones—empowering individuals through access to resources, as well as programs of support, education, wellbeing, and hope.

Crossroads4Hope Services:  We are experts in oncology and mental health, revolutionizing how we care for those facing cancer. Our services are at no cost to anyone and include professionally led individual and group support; education; distress screenings; nutrition and healthy cooking; health and wellness classes; and resources and referral. In addition to in-person and virtual programs, our digital platform, MyGo2Support, puts cancer support resources directly into patient’s and family’s hands via smartphone without having to download an app.
Global Colon Cancer Association Kiosk #A1

The Global Colon Cancer Association (GCCA) advocates for equitable access to quality colorectal cancer screenings, testing, treatments, and care, because where you live should not determine whether you can prevent or survive colorectal cancer. As both a membership-based umbrella organization and patient advocacy organization, GCCA amplifies and supports the efforts of our member organizations, develops adaptable advocacy and educational materials for our members, and conducts our own advocacy, education, and patient-centered policy initiatives.

Global Resource for Advancing Cancer Education (GRACE) virtual only

The Global Resource for Advancing Cancer Education (GRACE) provides expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care. cancergrace.org/

Founded in 2007 by Dr. Howard (Jack) West, GRACE democratizes cutting-edge cancer care by disseminating medical information through live/on-demand programs, webinars, podcasts, and written materials, aimed to educate patients and caregivers. GRACE fosters community engagement and knowledge sharing through their online forum, bridging the gap between medical professionals and patients. GRACE exemplifies breaking down barriers in cancer care, enhancing accessibility and understanding.

GO2 for Lung Cancer Kiosk #A16

GO2 for Lung Cancer transforms survivorship by working across the entire continuum of care for those who are at-risk or diagnosed with lung cancer. Support services include:

- Helpline- 1:1 support by phone, email, and website
- LungMATCH- Treatment and trial navigation
- Phone Buddy Program- Peer matching support
- Lung Cancer Living Room Series- Expert speakers share about lung cancer topics
- Gathering Hope-monthly virtual social
- Online community through HealthUnlocked
- Free educational publications on a wide variety to of topics

Head and Neck Cancer Alliance Kiosk #A4

Head and Neck Cancer Alliance strives to serve as a One-stop Center for patients, survivors, and family members seeking support and information about head and neck cancer. From the management of symptoms to treatment options to clinical trials, HNCA works in partnership with medical and healthcare partners to provide up-to-date educational information, activities to promote awareness and education, and resources for patients to engage and learn from one another. We develop strategic priorities to tackle the challenges facing those impacted by this disease.

HealthTree Foundation virtual only

HealthTree is a nonprofit organization uniting patients and researchers through cutting-edge technology to work together on curing diseases. HealthTree provides lifetime personalized support and education to patients, meaningful patient-to-patient connections, and a powerful patient data portal, which transforms patients into active contributors of research that drives lifesaving breakthroughs. Visit healthtree.org

Imerman Angels Kiosk #A8

Imerman Angels' mission is To provide comfort and understanding for all cancer fighters, survivors, previvors and caregivers through a personalized, one-on-one connection with someone who has been there. Your one-on-one cancer community- so no one has to face cancer alone.

The Leukemia & Lymphoma Society Kiosk #A3

The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary (nonprofit) health organization dedicated to funding blood cancer research, support, and advocacy. The LLS mission is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. The mission is carried out through research, patient and professional education and services, and advocating for cures and access to care.

LLS provides free support, resources, and referrals, as well as virtual and local in-person education programs and videos to help all patients, survivors and their families stay informed about and access to the best possible treatment and follow-up care. LLS patient services include financial assistance, transportation and urgent need assistance, one-on-one peer-to-peer support, nutrition counseling, online chats and forums, and support groups. Services also include up-to-date disease and treatment information provided through the LLS website and printed booklets, as well as through one-on-one dialogue with Information Specialists and Clinical Trial Navigators in LLS’s Information Resource Center (IRC) and the Clinical Trial Support Center (CTSC). The IRC and CTSC are on the front lines of LLS’s efforts to improve patient access to quality care and to improve
Patient Advocacy Pavilion

Patient Advocacy Pavilion offers various resources and support for patients and their families. LLS, for example, educates healthcare professionals about advancements in blood cancer research, treatment, side-effects management, resources for patients, and communicating with their patients about clinical trials. To access free CE/CME activities and resources visit www.LLS.org/CE.

LiveLung Kiosk #A6
LiveLung is on a mission to improve health outcomes by advancing lung cancer education, early detection, and compassion for people impacted by lung cancer. We do this by hosting a network of monthly educational community lung cancer patient groups. We provide resource bags to dozens of cancer centers where nurse navigators give them to newly diagnosed lung cancer patients. We are a 501(c)(3) nonprofit organization, here to serve the lung cancer community.

The Myelodysplastic Syndromes Foundation Inc. virtual only
The MDS Foundation is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases. The MDS Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases.

Say YES to Hope Kiosk #A13
Say YES to Hope is changing the world of advanced cancer through outreach, education, support, and hope. We are committed to serving these oft forgotten cancer patients as the association between access to care and support creates increased survival, better outcomes, and improved quality of life YES is a champion in the advanced cancer advocacy community. We are challenging you to join us and “bee the change” in the fight against advanced cancer!

Sharsheret Kiosk #A10
Sharsheret is a national not-for-profit organization that supports women and families facing breast or ovarian cancer, or who are at higher diagnostic risk. Our free, confidential support includes access to social workers, a genetic counselor, and a range of programs, including financial subsidies, to help women a navigate cancer diagnosis. Sharsheret has a wide array of educational brochures for you to share with patients and offers free professional training for your team (CE credit may be available). For more information or to order resources, visit us at www.sharsheret.org or call us at (866) 474-2274.

Tigerlily Foundation Kiosk #A2
Tigerlily Foundation is one of the premier global organizations providing education, awareness, advocacy, empowerment and transformational programs to girls, young women, breast cancer survivors, metavivors, and caregivers – before, during and after breast cancer. Our programs impact young women of diverse ethnic backgrounds, underserved communities and those facing health disparities. Our programs also incorporate spirituality, holistic health, prevention, wellness, support, and survivorship programs to help you live your best life.

Tigerlily's ANGEL Advocacy Program provides comprehensive training for women of color between the ages of 21 – 50, who have been impacted by breast cancer. Contact us today to learn more!

Triage Cancer Kiosk #A15
Triage Cancer is a national, nonprofit organization that provides free education on legal and practical issues that may impact individuals diagnosed with cancer and their caregivers, through events, materials, and resources.

Veterans Prostate Cancer Awareness Kiosk #A7
Veterans Prostate Cancer Awareness (VPCA) is a nonprofit organization dedicated to promoting prostate awareness in the Veteran Population. The Goals and Mission of VPCA are to:

- Provide prostate cancer educational information and promote awareness among US Veteran population.
- Educate Veterans on screening, and available treatment options when faced with a prostate cancer diagnosis and empower Men to become their own Health Advocates.
- Promote new technologies for the treatment and cure of prostate cancer.

Young Adult Survivors United (YASU) Kiosk #A12
Young Adult Survivors United (YASU) provides emotional, social, and financial support to young adult cancer patients & survivors aged 18-45 when diagnosed and their caregivers/co-survivors, enhancing their quality of life and hosting an age-appropriate community they need for peer support. Our virtual platform outreaches across the U.S. with in-person programming in Pittsburgh, PA where it is headquartered. Additional programs include free daylong or overnight respite trips, self-love workshops, and educational wellness seminars.
Did you know….

• Veterans are 40% more likely to develop Prostate Cancer?

• 15,000 new cases are diagnosed in the VHA System each year?

• There are over 500,000 Veterans in the VHA living with Prostate Cancer?

• You should screen early for prostate cancer if you are a Veteran?

Saving Veterans through Education, Awareness & Advocacy

www.VPCa.vet

WE CAN HELP!

RESOURCES FOR PATIENTS:
• Free educational webinars
• Annual Head & Neck Cancer Symposium
• Support services (mentors, online forum, nurse navigator)
• Gas card program

RESOURCES FOR MEDICAL PROFESSIONALS:
• Brochures for your office
• HNC screening kits
• Awareness Month press release templates, social media, and more

SIGN UP FOR OUR NEWSLETTER

PARTNERS IN CARE FOR HEAD & NECK CANCER PATIENTS
Explore the clinical profile of LIBTAYO across multiple indications

Visit Regeneron Booth 800 at NCCN or Libtayohcp.com

April 5-7, 2024
Orlando World Center Marriott
Orlando, FL

Click here to learn more
Explore the clinical profile of LIBTAYO across multiple indications

To learn more scan here or visit LIBTAYOhcp.com
Awareness. Education. Advocacy.

The Global Colon Cancer Association (GCCA) provides medically accurate patient educational materials about CRC biomarkers and their treatment impact, as well as patient stories and advocacy resources through our Know Your Biomarker program at knowyourbiomarker.org.

You can also find patient materials on CRC signs and symptoms, screening, prevention, and treatment on the GCCA website at globalcca.org/learn/colorectal-cancer.

Scan this QR code to receive our printed materials by mail. You can also download printable files on our website.

CONFRONTING LUNG CANCER STARTS HERE.

From the realization of risk to the moment of diagnosis, from finding care to staying informed and building your resources, we relentlessly advocate for all people at risk and living with lung cancer to confront the disease.

As your friends, your guides, your teachers, your advocates and your support system, GO2 is your go-to.

Learn more at go2.org.

Helpline: 1-800-298-2436
ANAL CANCER FOUNDATION
Our Resources for Patients

Peer-to-peer support program
Side effect management resources
and more!

SPREAD THE WORD!

✉️ info@analcancerfoundation.org
🌐 analcancerfoundation.org

CCF’s Nursing Advisory Board

The Nursing Advisory Board (NAB) is comprised of nursing professionals (RN, MSN, DNP) with expertise in the management of patients with cholangiocarcinoma and who are currently practicing in cancer research centers throughout the United States.

MEMBERSHIP

Applications are accepted for review by NAB and CCF leadership. Membership may also be at the invitation of NAB leadership team. While there are no term limits, active participation is required for the following:

- Quarterly Meetings (virtual)
- Attendance at the Cholangiocarcinoma Foundation Annual Conference

PURPOSE

The NAB works collaboratively to generate and distribute education on various platforms that are specific to the treatment, care, and management of patient’s with cholangiocarcinoma. In conjunction with the Medical Advisory Board and the CCF patient advocacy team, the NAB tailors material to the needs of patients, caregivers, and local healthcare professionals who are caring for patients with CCA and include but are not limited to the following:

- Clinical nursing practice guidelines
- CCF annual conference presentations/uploads
- Patient/caregiver educational series through CCF webinars
- Abstract and poster presentations at national cancer conferences

for more information, please visit curecca.org/nab
Tigerlily offers comprehensive programming across the continuum of breast health research, screening, prevention, and treatment to dismantle disparities and increase access to the care patients deserve.

We are committed to mobilizing our community of young women, caregivers, and loved ones to transform lives and recognize that we must Advocate Now to Grow, Empower & Lead through the ANGEL Advocacy Program.

The Clinical Trials Program is a transformational initiative to accelerate the delivery of innovative treatments to our patients with a strategic focus on populations that face the highest disparities.

To ensure patients and healthcare providers have the right resources at their fingertips to better equip patients and caregivers as they navigate a cancer diagnosis, download our Barrier Toolkits.

In partnership with WITT Forever, the RAISE platform makes it easy for patients to get resources and assistance for support and empowerment without feeling as though they are burdening others.

Learn about these programs and more by visiting the Tigerlily website and following us on social media!

— info@tigerlilyfoundation.org — @tigerlily_foundation — @tigerlilycares — @tigerlilyfoundation

TRIAGE CANCER

Our mission:
Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers, through events, materials, and resources.

We provide FREE resources for:
• Cancer Patients
• Caregivers
• Health Care Providers

On important topics:
• Insurance
• Work
• Finances
• Caregiving
• & More

“Triage Cancer…They fill a gap in support that makes life tangibly better for people with cancer and their families.”

Learn more at TriageCancer.org
If you or a loved one is interested in being connected with a CAR T-cell therapy navigator to learn about support and available resources - call or visit us online.

844-792-6517
cancersupportcommunity.org/
car-t-navigation-referral

Brought to you by:

WE’RE HERE TO HELP YOUR PATIENTS.

A blood cancer diagnosis can be overwhelming for your patients. Blood cancer patients, including those with leukemia, lymphoma, myeloma, myelodysplastic syndromes and myeloproliferative neoplasms can find hope, education, guidance and support from The Leukemia & Lymphoma Society (LLS).

Our Information Specialists complement the care you provide with FREE, in-depth personalized services that connect patients to financial assistance, patient education (including booklets, podcasts and webinars), online and in-person support, nutrition consultations and the LLS Clinical Trial Support Center for assistance with clinical trials.

Please contact us at 800.955.4572 or go to www.LLS.org/resources-healthcare-professionals.
Join the Foundation for Women’s Cancer to #MoveTheMessage

With this campaign, our goal is to increase awareness of gynecologic cancers, starting with historically marginalized communities, through dissemination of critical patient education resources.

Educational materials available for download @ MovetheMessage.org
Bling4Cancer is a collection of sparkling crystal beads, charms and awareness ribbons in 20 colors to correspond with all cancer and medical illness awareness colors. Choose from pre-designed items or create a custom made look! They’re vibrant accessories that can fashionably honor someone who has been touched by cancer. Quantity discounts available.

About Us
We offer emotional, social, and financial support to enhancing the quality of lives for YA cancer survivors and their caregivers/co-survivors.

Contact Us
724-719-2273
www.yasurvivors.org

Programs
Virtual Supportive Chats
Self-Love Workshops
Financial Assistance
Free Respite Trips
Social Activities
Educational Seminars
Free Counseling (regional)
Caregiver/Co-Survivor Support
Hybrid Programming

Proceeds support life-saving cancer initiatives

We offer volume discounts for non-profit groups & healthcare providers

Available online at
www.normaleah.org

Bling4Cancer
We offer volume discounts for non-profit groups & healthcare providers

Available online at
www.normaleah.org
Try your science saves lives. Telling its story is an art.

We’ve been a trusted partner of the nation’s top academic medical centers and comprehensive cancer centers for nearly 40 years.

STEEGETHOMSON.COM/CANCER

BRAND + STRATEGY  
PR + VISIBILITY  
PHILANTHROPIC 
COMMUNICATIONS
Do You Know What You Need To Know?

CONTACT US TO SCHEDULE A TRAINING!
MROSEN@SHARSHERET.ORG

Www.sharsheret.org

ASSOCIATION OF CANCER CARE CENTERS
Celebrating 50 years of innovation, education and advocacy and serving more than 40,000 members of the cancer care community

ACCC
ASSOCIATION OF CANCER CARE CENTERS™

50 Years STRONG

Engage with Us Today!

Scan the QR code or visit accc-cancer.org to learn more about ACCC.

TRAININGS INCLUDE:

• The Impact of Culturally Competent Cancer Care
• Finding a New Normal: Helping Your Patients Manage Survivorship
• Hereditary Breast and Ovarian Cancers in the Jewish Community
• Coping with Cancer: A New Approach to Reduce Cancer-Related Stress in Patients

We can create additional trainings based on the specific needs of your health care team.
# General Poster Session I

**Hosted by NCCN Oncology Research Program (ORP)**

**Session I Friday, April 5**

**Breakfast 7:30 - 8:30 AM | Morning Break 9:45 - 10:05 AM**

**Lunch 11:55 AM - 1:10 PM | Afternoon Break 3:15 - 3:35 PM**

<table>
<thead>
<tr>
<th>#</th>
<th>Presenting Author and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chad Tang, MD&lt;br&gt;The University of Texas&lt;br&gt;MD Anderson Cancer Center&lt;br&gt;NCCN Member Institution</td>
<td>Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial</td>
<td>Kieko Hara, MD; Alexander D. Sherry, MD; Alejandra G. Serrano, MD; Larisa V. Kostousov, MD; Shara D. Hernandez, MD; Wei Lu, MD, PhD; Li Shen, MD; Amisha V. Shah, MD; Eric Jonasch, MD; Jose A. Karam, MD; Suren F. Matin, MD; Nizar Tannir, MD; Jing Wang, PhD; Pavlos Msaouel, MD, PhD; Kanishka Sircar, MD; Luiza Solis, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>2</td>
<td>Zachary A. K. Frosch, MD&lt;br&gt;Fox Chase Cancer Center&lt;br&gt;NCCN Member Institution</td>
<td>Patients’ Perspectives on Being Treated by Multiple Care Teams for Autologous Transplant/CAR-T Eligible Lymphoma and Multiple Myeloma</td>
<td>Clark Meshack, MPH; Caitlin Meeker, MPH; Aysa Varshavsky-Yanovskiy, MD, PhD; Rashmi Khanal, MD; Michael Bromberg, MD, PhD; Ashwin Chandar, MD; Emmanuel Quen, MD; Jordan Carter, MD; Shazia K. Naik, MD; Marcus Messmer, MD; Charissa Montgomery, MS; Jason A. Incorvati, MD; Nadia D. Ali, MD; Michael J. Styler, MD; Carolyn Y. Fang, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>3</td>
<td>Christos Fountzilas, MD&lt;br&gt;Roswell Park Comprehensive Cancer Center&lt;br&gt;NCCN Member Institution</td>
<td>A Phase I Study of TAS102 Plus Talazoparib in Advanced Colorectal (CRC) and Esophagogastric (EGC) Adenocarcinomas</td>
<td>Agnieszka Witkiewicz, MD, Sarah Chatley, BS; Victoria Fitzpatrick, DNP; Justin Zonneville, MS; Mohammed Atiwah, MD; Hanna Rosenheck, MD; Donald Magee, PharmD, PhD; Jianxin Wang, PhD; Anuradha Krishnamurthy, MBBS; Benjamin Switzer, DO; Kristopher Attwood, MD; Igor Puzanov, MD; Renuka Iyer, MD; Andrei Bakin, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>4</td>
<td>Ana Tergas, MD, MPH&lt;br&gt;City of Hope National Medical Center&lt;br&gt;NCCN Member Institution</td>
<td>Genetic Ancestry and Genomic Alterations of Cervical Cancer in a Diverse Patient Population</td>
<td>Sara Byron, PhD; Guangfa Zhang, PhD; Tyler Izatt, MS; Jiaming Zhang, PhD; Nicholas Schork, PhD; Lorna Rodriguez, MD, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>5</td>
<td>Abhishek Chakraborty, PhD&lt;br&gt;Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute&lt;br&gt;NCCN Member Institution</td>
<td>The NF-I/a Transcription Factor Is a HIF-Independent Oncogenic Dependency in Kidney Cancer</td>
<td>Shannon Zayas, MD; Tieg Grubb, BS; Fensheng Kuo, PhD; Eduard Reznik, PhD; A. Ari Hakimi, MD; Abhishek Chakraborty, PhD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>6</td>
<td>Richard Tobin, PhD&lt;br&gt;University of Colorado Cancer Center&lt;br&gt;NCCN Member Institution</td>
<td>MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases</td>
<td>Elizabeth N. Katsnelson, BS; Kasey L. Couts, PhD; Andrea Spengler, BS; Liyen Lo, PhD; Laurent Gapin, PhD; Martin D. McCarter, MD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>7</td>
<td>Shuang George Zhao, MD&lt;br&gt;University of Wisconsin&lt;br&gt;Cancer Center&lt;br&gt;NCCN Member Institution</td>
<td>Liquid Biomarkers of Response to Radium-223 in Metastatic Prostate Cancer</td>
<td>Grace Blitzer, MD; Jamie Sperger, PhD; Menggang Yu, PhD; John Floberg, MD; Marina Shurfitt, MD; Joshua Lang, MD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>8</td>
<td>Lauren Laderman, MD&lt;br&gt;Fox Chase Cancer Center&lt;br&gt;NCCN Member Institution&lt;br&gt;ORP-Funded Study</td>
<td>Does Routine Clinical Assessment of Older Adults with Gastroesophageal Cancer Tell the Whole Story?</td>
<td>Meghan Connors, BS; Caitlin R. Meeker, MPH; Elizabeth A. Handorf, PhD; Kelly A. Filchner, PhD; Mohamedtaki A. Tejani, MD; Grant R. Williams, MD, MSPH; Arthur Winer, MD; Sukeshi P. Arora, MD; Namrata Vijayvergia, MD; Efrat Dotan, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>9</td>
<td>Elham Nasrollahi, MD&lt;br&gt;UPMC Pinnacle Harrisburg</td>
<td>Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed with Hepatocellular Carcinoma</td>
<td>Adalberto Guzman, MD; Anas Atrash, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>10</td>
<td>Dena Berhan, BS&lt;br&gt;Moffitt Cancer Center&lt;br&gt;NCCN Member Institution</td>
<td>Implementation of an Integrated Supportive Care Medicine Consultation Service within a Gastrointestinal Cancer Clinic: Timeliness of Referrals and Patient Access</td>
<td>Nicole Nardella, MS, BS; Adrianna Craigat, BS; Denny Lu, HS; Sarah Goodchild, BS; Terry Gruchow, PA-C, MHS, DFAAPA; Young Chang, MD; Sahana Rajasekhar, MD; Pamela Hodul, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>11</td>
<td>Ujjwal Karki, MBBS&lt;br&gt;Corewell Health William Beaumont&lt;br&gt;University Hospital</td>
<td>Dynamic Changes in Circulating Tumor DNA Predicts Disease Progression or Regression in Colorectal Cancer</td>
<td>Bipin Ghimire, MBBS; Emma Trentacosta, MD; Mohammad Chisti, MD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----</td>
<td>-------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------</td>
</tr>
<tr>
<td>12</td>
<td>Ericson John Torralba, BSc Wright State University Boons</td>
<td>Microwave Ablation versus Resection versus Stereotactic Body Radiation Therapy of Stage IA Non-small Cell Lung Cancer in US Veterans</td>
<td>Garrett Fisher, BSc; Reid Fursmidt, MSc; Michael Gilbert, BSc; Perry Nystrom, MD; Albert Malcom, MD; John Mathis, MD; Robert Short, MD, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>13</td>
<td>Jose Rivera, IE, MBA The University of Texas MD Anderson Cancer Center NCCN Member Institution</td>
<td>A Safety Net System for Significant Diagnostic Imaging Actionable Findings at a Comprehensive Cancer Care Center</td>
<td>Carmen Gonzalez, MD; Tonita Bates, DNP, APRN</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>14</td>
<td>John Sharp, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute NCCN Member Institution</td>
<td>Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies</td>
<td>Cassandra Pasaday, AB; Songzhu Hao, MS; Lai Wei, PhD; Carolyn Presley, MD; Dwight Owen, MD, MS; Kathleen Wyne, MD, PhD; Alexa Meara, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>15</td>
<td>Mylineh Nam, BA Kaiser Permanente Bernard J. Tyson School of Medicine</td>
<td>Development of Heart Failure Following Anthracycline Exposure in Survivors of Adolescent and Young Adult Cancer in an Integrated Healthcare System</td>
<td>Mark Duggan, MA; Chun Chao, PhD; Robert Cooper, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>16</td>
<td>Asim Waqas, PhD Moffitt Cancer Center NCCN Member Institution</td>
<td>Hierarchical Multimodal Learning on Pan-Squamous Cell Carcinomas for Improved Survival Outcomes</td>
<td>Aakash Tripathi, BS; Ashwin Mukund, MS; Paul Stewart, PhD; Mia Naeini, PhD; Ghulam Rasool, PhD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>17</td>
<td>Cinzia Caparso, PhD University of Michigan Rogel Cancer Center NCCN Member Institution</td>
<td>“Share the Fear”: Communication Concerns of Parents with Cancer with Dependent Children for their Co-parent: A Qualitative Study</td>
<td>Zoe Bowen, BS; Sung Won Choi, MSc, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>18</td>
<td>Tongmei Zhang Beijing Chest Hospital</td>
<td>Aneuploid Epcam + Disseminated Tumor cells (DTCs) Correlated with Liver Metastasis and Independently Predict Poor Survival in Small Cell Lung Cancer</td>
<td>Ying Wang; Hongxia Li; Bachua Lu; Yuan Gao; Yanxia Liu; Lina Zhang; Mingming Hu; Hongmei Zhang</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>19</td>
<td>Sara Tavera Alam, MD McGovern Medical School</td>
<td>Real-World Outcomes in Patients with Burkitt Lymphoma in a Safety-Net Health System</td>
<td>Jun Y. Jiang, MD; Chihoke Nze, MD, MPH; Danielle Guffey, MS; Rocklaun Kim, MD, PhD; Abidun O. Okyoni, PhD; Omar Rosales, MPH; BS, Raka Bandyo, MS; Courtney N. Miller-Chism, MD, Mark M. Udden, MD; Martha P. Mims, MD, PhD; Hilary Ma, MD; Gustavo A. Rivero, MD; Akiva Diamond, MD; Pumima S. Teegavarapu, MD; Christopher R. Flowers, MD, MS; Ang Li, MD, MS; Marie Lee, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>20</td>
<td>Abha Kulkarni, MD, MPH New York-Presbyterian Weill Cornell Medical Center</td>
<td>Surviving and Thriving After Lung Cancer: A Pilot Project to Understand Physician Perspectives on the Approach to Lung Cancer Survivorship Care at Weill Cornell Medicine Medical Oncology</td>
<td>Christine Garcia, MD, MPH</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>21</td>
<td>Nicole Nardella, MS, BS Moffitt Cancer Center NCCN Member Institution</td>
<td>Personalizing the Patient Experience: Understanding the Emotional State and Learning Preferences of Pancreatic Cancer Patients Receiving Multidisciplinary Care</td>
<td>Brian Gonzalez, PhD; Matt Adams, BS; Corinne Thomas, BS; Adrianna Draiat, BS; Maria Sandoval, MD; Jessica Frakes, MD; Russell Palm, MD; Carrie Stricker, MD; Joseph Herman, MD; Pamela Hodul, MD; Sarah Krug, MS; Sarah Hoffer, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>22</td>
<td>Kashyap Patel, MD Carolina Blood and Cancer Care Associates</td>
<td>Real-World Clinical Benefit Among Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept</td>
<td>Brandy Snyder, PharmD; MBA; Derek Tang, PhD, BPharm; Debajana Chatterjee, PhD; Anupama Vasudevan, PhD; Vichetruku Mordi, PharmD, MS; Harvey Katzen, MD; John Li, PhD; MPH; Lindsay Alon, MHSA; Ali McBride, PharmD, MS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>23</td>
<td>Simi Aggarwal, PhD Graticule Inc.</td>
<td>Prior SARS-CoV-2 in Patients with CAR-T Negatively Impacts Overall Survival, Highlighting the Need for Targeted Prophylaxis Strategies</td>
<td>Andrew Ip, MD; Yuval Koren, MSc; Dan Poscow, MBA; Catia Ferreira, PhD; Lisa Glasser, MD; Kathleen Heil, BSN; Della Varghes, PhD, MPH; Sudhir Venkatesan, MPH, PhD; Carla Talarico, PhD, MPH</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>25</td>
<td>Erin Comerford, MS Sanofi-Aventis US LLC</td>
<td>Patient-Reported Outcome (PROM) Data in Oncology NDAs Approved by the FDA (2018-2021): A Review of Criticism and Concerns in Comments from Regulators</td>
<td>Lindsay Norcross, MA; Medha Sasane, PhD; Ying Zheng, MS, MHSA; An Gnanasakthy, MSc, MBA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>26</td>
<td>Atharv Sharma, BE 2S Associates</td>
<td>Impact of Social Determinants (SDOH) on Surgery and Patient Outcomes in Early-Stage Non-Small Cell Lung Cancer (enNSCLC)</td>
<td>Manu Prasad, MBA; Tianyuan Hu, MPH; Arunav Sakkia, MS; Prabhakar Gaur, B. Tech; Venkata Sai Sumanth Pulluri, B. Tech; Stuti Jha, B. Tech</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>27</td>
<td>Atulya Aman Kholas, MD</td>
<td>Predicting Disparities in Adverse Dispositions Following Major Surgery for Lung Cancer Using Machine Learning</td>
<td>Vijval Rajan, BS; Mohammad Affat Gariyani, MD; Nitya Batra, MD; Karan Jawbri, MD; Rohit Singh, MD; Yanji Zhang, PhD; Zhenwei Zhang, PhD; Ashfaq Ahmed, PhD; Mukesha Roy, PhD; Venkataraghavan Ramamoorthy, MD; Muni Rubens, MD, PhD; Anshul Saxena, PhD; Aakash Desai, MD; Ishmael Jaiyesimi, MD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>28</td>
<td>Sasmith Menakuni, MD</td>
<td>Lung Cancer In Never Smokers: The Role of Radon Exposure and Public Knowledge</td>
<td>Vijayal Dhillon, MD; Marriam Ali, MD; Ahmed Salih, MD; Nasser Hanna, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>29</td>
<td>Vaishnavi Singh, MD</td>
<td>Educational Efficacy of YouTube Videos on Multiple Myeloma</td>
<td>Shiva Jashwath Gaddam, MD; Poomimma Ramadas, MD; Samip Master, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>30</td>
<td>Shelley Ellis, MA, PhD</td>
<td>Development and Pilot Testing of a Comprehensive Set of Measures for Organizational Assessment of NCCN Guideline Recommended Genomic Testing</td>
<td>Aaron Katz, PharmD, PhD; Chao Huang, MD; Samuel Boyd, MS; Carolyn Caine, MA; Whitney Onasch, MBA; Daniel Farrell, MD, PhD; Jeffrey Thompson, PhD; Joaquina Baranda, MD; Rashna Madan, MD; Wei Zhang, MD; Zseraldina Ferenczi, MPH; Andrew K Godwin, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>31</td>
<td>Julie Wiedower Kaylor, PhD, CGC</td>
<td>Utilization of Biomarker Testing and Biomarker-Driven Targeted Therapy Among Patients with Metastatic Non-small Cell Lung Cancer</td>
<td>Julie Wiedower Kaylor, PhD, CGC; Karen M. Stockli, PharmD; Jacqueline Lekostaj, MD, PhD; Jamie Tucker, MS; Shaun F. Forbes, PhD; Julia M. Certo, MPH; Caroline Wespert, MS, CGC; Keelia Clemens, PhD, MS, CGC; Lucy Langer, MD, MSHS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>32</td>
<td>Sangam Sangam, MD</td>
<td>Mesothelioma: Trends in Palliative Care Utilization in Hospitalized Patients, a National Inpatient Sample (NIS) Study (2016-2020)</td>
<td>Marco Bermudez, MD; Francisco Gallegos Koyner, MD; Tripti Jain, MD; Shorabah Sharma, MD; Sorab Gupta, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>33</td>
<td>Misbahuddin Syed, MD</td>
<td>Instituting Quality Improvement Processes with Periprocedural Heparin Infusions at a Major Cancer Center Utilizing a Failure Mode and Effects Analysis</td>
<td>James Lochner, CSSBB, MBA, MSQA; Katherine Hetzel, MSN, RN, OCN; Misbahuddin Syed, MD, FACP</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>34</td>
<td>Jonathan C. Bastick, III, BS</td>
<td>High Dose Rate Intestinal Brachytherapy for Squamous Cell Carcinoma of the Vagina: Methods and Outcomes at a Single Institution</td>
<td>Andrés Portocarrero Bonifaz, MSc; Bryce Forry, BA; Maxwell Kassel, MSc; Salman Syed, MD; Grant W. McKenzie, MD; Keith T. Sowards, MSc; Jeremy T. Gaskins, PhD; Scott R. Silva, MD, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>35</td>
<td>Diego Garmendia, BA</td>
<td>Comparing Cancer Risk Management Between Females with Truncating CHEK2 1100delC versus Missense CHEK2 1157T Variants</td>
<td>Anne Weidner, MPH; Lindsay Vento, BSc; Tuya Pal, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>36</td>
<td>Adam Khorasanchi, MD</td>
<td>Overall Survival (OS) Impact for NSCLC Patients with IRAE and Non-IRAE Hospital Admissions During First line Pembrolizumab Treatment</td>
<td>Songzhu Zhao, MS; Lai Wei, PhD; Mingxia Li, MD; Kevin Ho, MD; Hamzaat Abu-Shih, MD; Evelyn Goodyear, BS; Austin Secor, BS; Peter Shields, MD; Kai He, MD, PhD; Jacob Kaufman, MD, PhD; Regan Memmott, MD, PhD; Asrar Alahmadi, MBBS; David Carbone, MD, PhD; Gregory Otterson, MD; Alexa Meara, MD; Carolyn Presley, MD; Dwight Owen, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>37</td>
<td>Janice DallaCosta, BSN, MBA</td>
<td>Joining Forces to Minimize Hypomagnesemia in Patients Receiving Cisplatin and Cetuximab Infusions</td>
<td>Patrick Skewffington, PharmD, MHA, MSRA; Ny Tran, MSN</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>38</td>
<td>Keyi Jia, MD</td>
<td>Combining Immunotherapy and Anti-angiogenesis Remodeling the Immune-microenvironment of LKB1/KEAP1-mutant Non-small Cell Lung Cancer</td>
<td>Shengxiang Ren, MD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>39</td>
<td>Vincent T. Ma, MD</td>
<td>Microfluidic Characterization and Analysis of Circulating Tumor Cells from Patients with Metastatic Melanoma</td>
<td>Benjamin K. Gibbs, BS; Jennifer L. Schehr, PhD; Joshua M. Lang, MD; Vincent T. Ma, MD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>40</td>
<td>Cholathorn Wannaputh, MD</td>
<td>Pneumonitis Incidences in Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-analysis</td>
<td>Natcha Polphichai, MD; Pharat Siladech, MD; Manasawee Tanaryakul, MD; Phuuvadth Wattanachayakul, MD; Pakin Lalitthiti, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>41</td>
<td>Christine Vinci, PhD</td>
<td>A Mindfulness-based Intervention for Caregivers of Autologous Hematopoietic Stem Cell Transplant Patients: Pilot Study Results</td>
<td>Valerie V. Veppe, MMS; Sierra J. Washington, MPH; Sarah R. Jones, BA; L. Robert Gore, PhD; Sofia Fonseca, BA; Ranjita Poudel, PhD; Joseph Pidalas, MD, PhD; Christine Vinci, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>42</td>
<td>Priyal Agarwal, MD</td>
<td>A National Cancer Data Base (NCDB) Analysis of Prognostic Factors in</td>
<td>Anulya Yellala, MD; Samia Asif, MD; Valerie K. Shostrom, PhD; Meghana Kesireddy, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>NCCN Member Institution</td>
<td>Metastatic Triple-Negative Breast Cancer (TNBC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Julia Olsen, MS</td>
<td>Disparities in Real-World Screening Mammography Compliance Rates by</td>
<td>Scott Pohlman, MS; Jason Shames, MD</td>
<td>Outcomes and Health</td>
</tr>
<tr>
<td></td>
<td>Hologic Inc.</td>
<td>Body Mass Index and Mobility-Restricting Diagnosis – A Commercial</td>
<td></td>
<td>Services Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Claims-Based Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Anurag Kansal, PhD</td>
<td>Working and Cancer: The Impact of Cancer Diagnosis and Treatment on</td>
<td>Sarah A. Cohn, BS; Shelley Fuld Nasso, MPP; Elena M. Jeannotte, BA; Haley V. Smoot, MSc</td>
<td>Outcomes and Health</td>
</tr>
<tr>
<td></td>
<td>Grail LLC</td>
<td>Employment, Presenteemt, and Productivity</td>
<td></td>
<td>Services Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Daniel Simmons, PharmD, MS</td>
<td>Treatment Patterns in Surgically Resected NSCLC Since the Introduction</td>
<td>Daniel Simmons, PharmD, MS; Lu Zou, PhD; Yahan Zhang, MS; Wale Qaybanji, MD; MBA; MPH;</td>
<td>Outcomes and Health</td>
</tr>
<tr>
<td></td>
<td>Moffitt Cancer Center</td>
<td>of ImmunoOncology Agents</td>
<td>Tiernan Mullooney, PhD</td>
<td>Services Research</td>
</tr>
<tr>
<td></td>
<td>NCCN Member Institution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Anirudh Goyal, MD</td>
<td>The Impact of the COVID-19 Pandemic on Cancer Treatments: A SEER</td>
<td>Ozaan Cysler, MD</td>
<td>Outcomes and Health</td>
</tr>
<tr>
<td></td>
<td>University of Michigan</td>
<td>Population Based Analysis</td>
<td></td>
<td>Services Research</td>
</tr>
<tr>
<td></td>
<td>Rogel Cancer Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCCN Member Institution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Ming Lee, MD, PhD</td>
<td>A Data-Driven Approach to Increase Lung Cancer Screening Rate in the</td>
<td>Antonia Leavitt, MD; Alison Ramey, MS; Janelys Jones, MS; Lazar Pagan, MD; Chunmoy Jani,</td>
<td>Epidemiology/Risks/</td>
</tr>
<tr>
<td></td>
<td>Sylvester Comprehensive Cancer</td>
<td>Cancer to the Catchment Area of an NCI-Designated Cancer Center</td>
<td>MD; Gilberto Lopes, MD; Raymond Balise, PhD; Erin Kobetz, PhD</td>
<td>Prevention</td>
</tr>
<tr>
<td></td>
<td>Center</td>
<td>via Community Outreach and Engagement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Sabeen Ahmed, PhD</td>
<td>Early Diagnosis of Cancer Cachexia Using Body Composition Index</td>
<td>Nathan Parker, PhD; Ghulam Rasool, PhD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td></td>
<td>Moffitt Cancer Center</td>
<td>as the Radiographic Biomarker</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCCN Member Institution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Yukako Otani, MD, PhD</td>
<td>Immune Cell Dynamics After Radiotherapy for Oligometastatic Prostate</td>
<td>Yukako Otani, MD; David Qi, BA; Isabella Rose Pompa, BA; Richard Ku Dzung, PhD; Rea Pittle,</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>Dana-Farber/Brighton and</td>
<td>Cancer</td>
<td>BA; Ella Chang, BA; Keisuke Otani, MD; PhD; Jennifer W. Yo, MD; Anthony L. Zietman, MD;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women's Cancer Center (Mass</td>
<td></td>
<td>Patrick M. Reeves, PhD; Elezer M. Van Allen, MD; Jason A. Estathouli, MD; DPHIL;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Cancer Center</td>
<td></td>
<td>David T. Miyamoto, MD, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCCN Member Institution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Arvind Dasari, MD</td>
<td>Efficacy of Fructoseinhib in Less Heavily Pretreated Patients (Pts)</td>
<td>Cathy Eng, MD; Sara Lornardi, MD; Rocio Garcia-Carbonero, MD; Toshiki Masuishi, MD;</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>The University of Texas</td>
<td>With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data from</td>
<td>Chiara Cremonilino, MD; Francois Ghiroghelli, PhD; Joleen Hubbard, MD; Tanios Bekai-Saab,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MD Anderson Cancer Center</td>
<td>FRESCO and FRESCO-2</td>
<td>MD; Jeremy Jones, MD; Rui-Hua Xu, MD; Lin Shen, MD; Jianming Xu, MD; Xuyan Bai, MD;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCCN Member Institution</td>
<td></td>
<td>Yanhong Deng, MD; YIng Yuan, MD; Wei Wei, MD; Jianchang Lin, PhD; Lucas Chen, MD;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Zhao Yang, PhD; William R. Schelman, MD; Shukui Qin, MD; Jin Li, MD</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Nishanth Thalambedu, MD</td>
<td>Demographics and Outcomes of Autologous Stem Cell Transplant Among</td>
<td>Phillip Farmer; Clyde Bailey; Lakshmi Yarlagadda, MD; Sameer A Ahadidi, MD; Sharmilan</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>University of Arkansas for</td>
<td>IgD Multiple Myeloma Patients</td>
<td>Thanedaradjan, MD; Maurizio Zangari, MD; Carolinia Schinke, MD; Frits VanRhee, MD;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical Sciences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Moazzam Shahzad, MD</td>
<td>Treatment Outcomes in VEXAS Syndrome in Patients with MDS: A Systematic</td>
<td>Muhammad Kashif Amin, MD; Muhammad Fareed Khalid, MD; Ahmad Basharat, MD; Jawad Noor, MD;</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>Moffitt Cancer Center</td>
<td>Review</td>
<td>Sakina Abbas, MD; Iqra Anwar, MBBS; Mohammad Armand Id2imi, MD; Michael Jagal, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NCCN Member Institution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Xinghua Cheng</td>
<td>Single Cell Spatial Proteomics Reveals the Heterogeneity and</td>
<td>Shun Lu, PhD; Xinghua Cheng, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>Shanghai Chest Hospital</td>
<td>Microenvironment Characteristics of Long-term Survival Patients of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Small Cell Lung Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Punneeth Indural</td>
<td>Managing Pharmaceutical Costs in the Oncology Care Model</td>
<td>Christine Bates, MSN, RN; Cyndie Harrelson, BSN, RN; Kate Wallace, BSN, RN; DCC, Ann</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td></td>
<td>McKesson Corporation</td>
<td></td>
<td>Sweeney; Meredith Jones, MS, BSN, BA; Karen Miller, BSN, RN; Marti Lariva, Pharm D; Susan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Meyer, Pharm D; Tiffany Mitchell, Pharm D; DSP; Jody Agema, Pharm D; Punneeth Indural</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Yu-Cheng Chang, MD</td>
<td>The Impact of Proton Pump Inhibitors on Paclitaxel in Advanced</td>
<td>Jumin Song, MD; Kuan-Yu Chi, MD; Pei-Chin Chen, MD; MSc; Aarushi Sudan, MD; Chin-Hsuan</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>Danbury Hospital</td>
<td>Breast Cancer Patients: A Systematic Review and Meta-</td>
<td>Huang, MD; Yu Chang, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Gustavo Garcia, MD</td>
<td>Red Cell Distribution Width and Putative Severity Markers as</td>
<td>Maha Hameed, MBBS; Kevin Cai Zhen, MD; Manuel Rosario, MD; Karen Harmand, MD; Wilhelmine</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td></td>
<td>Sarasota Memorial Hospital</td>
<td>Predictors of Short-Term Critical Illness in Hospitalized Cancer</td>
<td>Wiese-Rometsch, MD; Robert Smith, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Lynn Abbott-McCloud, MA</td>
<td>Underserved Patients Find Their Voice Through Newly Formed SCLC</td>
<td>N/A</td>
<td>Outcomes and Health</td>
</tr>
<tr>
<td></td>
<td>Dusty Joy Foundation/LiveLung</td>
<td>Community</td>
<td></td>
<td>Services Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>58</td>
<td>Dominique Lopez, BS</td>
<td>Contemporary Treatment Patterns for Patients Diagnosed with cT1a Renal Tumors: A National Cancer Database Study</td>
<td>Aden Swayne, BA; Armin Ghomeshi, BS; Nathan VanderVeer-Harris, BS; Pushan Prabhakar, MBBS; Arjun Pon Avudaiappan, MS; MCh; Ahmed Eldefrawy, MD; Murugesan Manoharan, MD; Jorge Caso, MD; Dominique Lopez, BS</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>59</td>
<td>Ellie Jhun, PharmD, PhD</td>
<td>Recommendation and Genotyping Discrepancies in DPYD for Oncology Patients</td>
<td>Jason D. Walker, PhD; HCLD (ABB); Ghada Elnashar, PharmD, MS; Julie Ceno-England, MD; Annamarie Hawe, MPH; Cathryn Jennisenn, PharmD, BCOP; Victor Tam, PharmD; James Kelley, MD, PhD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>60</td>
<td>Yasunari Sakamoto, PhD, MD</td>
<td>Compliance with Recommendations and Clinical Practices Increased After Publication of the Japanese Clinical Practice Guidelines for Pancreatic Cancer 2022 Edition</td>
<td>Takuji Okusaka, MD; Masahiro Yoshida, MD; PhD; Masafumi Nakamura, MD; PhD; Masayuki Kimoto, MD; PhD; Yoshonori Ito, MD, PhD; Nobumasa Mizuno, MD, PhD; Keiji Hanada, MD, PhD; Masato Ozaka, MD; Chiguza Moricane, MD, PhD; Akiko Okumura, Toshio Fukuoka, MD; Yoshifumi Takeyama, MD, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>61</td>
<td>Christopher Armstrong, MS</td>
<td>Sociodemographic Trends and Regional Disparities Associated with Leukemia in Florida: Implications of an Aging-Population on Leukemia Incidences and Mortalities in the United States</td>
<td>Rebecca Kaiser, BS; Christopher Armstrong, MS; Nancy Elliott, PhD; Justin Taylor, MD; Raymond Balise, PhD; Erin Kobetz, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>62</td>
<td>Samantha Schimmel, BA</td>
<td>Prolonged Anesthesia as a Risk Factor for Extended Length of Stay Following Cranotomy for Primary Glioma</td>
<td>Jonath Gondor, BS; Adam Alayli, BS; Gavin Lockard, BS; Anshruta Dhanashkekar, BS; Vishnu V. Iyer, BS; Bassel El Sayed, BS; Samuel Bauserman, BS; Nasrin Aldawoodi, MD; Allan Escher, DO; Rahul Mhaskar, MPH, PhD; Nam D. Tran, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>63</td>
<td>Maya Gogtay, MBBS, MD</td>
<td>Does Immunotherapy Work in Patients With Poor Performance Status?</td>
<td>Omar Khaleed Abuhamameh, MBBS; Benjamin A. Teply, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>64</td>
<td>Mary Stanley, LMSW</td>
<td>Optimizing the Implementation of New Therapies in Multiple Myeloma</td>
<td>Craig Emmitt Cole, MD; David Vesole, MD; PhD; Mary Stanley, LMSW; Kimberly Demirhan, MBA, BSN, RN; Latha Shivakumar, PhD; Elana Plotkin, BS</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>65</td>
<td>Jennifer MacDonald, PharmD, BCOP</td>
<td>Institutional Policy Implementation for Allocating Chemotherapy During a Shortage</td>
<td>Carrie Hertzke, MBA, MD; Kelly Gaffney, PharmD, BCOP; Kristie Fleming, PharmD; Albert Craig Lockhart, MD; Carolyn Ann Gentles, DNP; LPN-C; Joshua Anenth, MD; Laura Sample, MHA, FACHE; Shelly Ozark, MD; HEC-C; Michelle Hudsph, MD; Grant Goodrich, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>66</td>
<td>Pushan Prabhakar, MBBS</td>
<td>Impact of Neoadjuvant Chemotherapy on Survival and Pathological Response Among Octogenarians who underwent Radical Cystectomy for Muscle-Invasive Bladder Cancer</td>
<td>Pushan Prabhakar, MBBS; Ahmed Eldefrawy, MD; Jorge Caso, MD; Murugesan Manoharan, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>68</td>
<td>Ruixuan Jiang, PharmD, PhD</td>
<td>Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study</td>
<td>Geoffrey Johnson, PhD; Emilie Scherrer, MSIC; John Kang, PhD; Kathleen M. Aguilar, MPH, PhD; Rohini Singh, MPH, MD; Eric D. Whitman, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>69</td>
<td>Jingbo Yu, MD, PhD</td>
<td>Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera Managed at Community Practices in the United States</td>
<td>Anupama Vasudevan, BDS, MPH, PhD; Harvey Katzen, MD, Evan Braunstein, MD, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>70</td>
<td>Carina Hernandez, MD, PhD</td>
<td>A Rare Case of Extranodal Primary Gallbladder Lymphoma Presented as Biliary Obstruction and treated with Rituximab and Lenalidomide</td>
<td>N/A</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>71</td>
<td>Jason Alter, PhD</td>
<td>Utilization of ExoDx Prostate Test for Prostate Cancer Risk Stratification in the African American Population</td>
<td>Ronald Tutrone, MD; Christian J. Ray, PhD; Sonia Kumar, PhD; Grannum Sant, MD; Yi Yuan Yao, MS; Visita Verma, MPH; Johan Skog, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>72</td>
<td>Zena Chahine, MD, University of Kentucky Markey Cancer Center</td>
<td>A Comparison of Somatic Mutations and ELN Classification in De Novo Acute Myeloid Leukemia Between Appalachian and Non-Appalachian Kentucky</td>
<td>Xitong Zhou, PhD, Anna Johnson, DO, Trevor Morris, MD, Ashley Soule, PharmD, Hifsa Taj, MBBS, Claire McCary, PharmD; Chaitanya Iragavarapu, MD; Renhold Munker, MD, Gregory Monohan, MD, Fezvi Yaliniz, MD, Ayman Qasrawi, MD, Reshma Ramiah, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>73</td>
<td>Carla Patel, DNP, The University of Texas MD Anderson Cancer Center NCCN Member Institution</td>
<td>Pumping Iron in the Preoperative Period: Is it Beneficial in Reducing Blood Transfusions?</td>
<td>Danielle Fournier, DNP, APRN, AGACNP-BC, Susan Knippel, DNP, APRN, FNP-C, Cheryl Fraser, MSN, APRN, ACNP-BC; TaCharra Laury, DNP, APRN, ACNP-BC; Hen Cao, MD, PA-C, Mini George, DNP, APRN, FNP-BC; Arlene Comea, PhD, Amber Akbar, PA-C</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>74</td>
<td>Broc Kelley, BS, University of Wisconsin Carbone Cancer Center NCCN Member Institution</td>
<td>Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native vs Non-Hispanic White Populations</td>
<td>Margaret R. Walker, MD, MPH, John M Hampton, MD, Syed Nabeeb Zafar, MD, MPH; Bibielle B Carroll, MD, MPH, PhD; Dana Hayden, MD, MPH, FACS, FASCRS; Andrea Schiefeleben, MSPH; Bret Benally Thompson, MD, Noelle K Loconte, MD, FASCO</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>75</td>
<td>Grant Andres, RN, Arizona Oncology Associates PC</td>
<td>Technology's Impact on implementing the NCCN Distress Thermometer in a Community-based Oncology Clinic</td>
<td>Kelly Huey, MSW, LCSW, Lorraine Lopez, BSN RN; Christine Bates, MSN, RN, CMHP; Maria Acosta, CMA; Cyndie Harrelston, BSN RN; Donald Brooks, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>76</td>
<td>Rachel Mea, MSN, RN, Jillian K. Tuizo, MSN, RN, AGCNS-BC, OCN Abramson Cancer Center at the University of Pennsylvania NCCN Member Institution</td>
<td>Implementation of an USG Peripheral IV Placement Program</td>
<td>N/A</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>77</td>
<td>Chalothorn Wannaphut, MD, John A. Burns School of Medicine</td>
<td>Organometallics as a Predictive indicator of Leukemia Cutis in the Patients with Acute Myeloid Leukemia</td>
<td>Chanaakarn Kanithammyom, MD; Pervadee Pattanaprachakul, MD; Smith Kungwankiatichai, MD; Weerapat Owattanapanich, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>78</td>
<td>Chi-Yin Liao, PhD, Ei Lilly and Company</td>
<td>Real-world Treatment Patterns and Effectiveness of Selpercatinib in Patients with Locally Advanced/metastatic Non-small Cell Lung Cancer in the US</td>
<td>Carmen Gonzalez-Ferrer, MSc; Samuel Whipple, PhD; Naleen Raj Bhandari, PhD; Patrick M. Peterson, PhD; Scott S. Barket, PhD; Feng Wang, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>79</td>
<td>Teresa Pardo, MSc, Fundación ECO</td>
<td>Molecular Tumor Boards Excellence. Phase 1 - State of the Art in Spain</td>
<td>Beatriz Belosillo, MD, PhD; Miguel Angel Caleja, PhD, Jesus Garcia-Foncillas, MD, PhD, Fernando Lopez-Rios, MD, PhD; Laura Mezquita, MD, PhD; Luis Paz-Ares, MD, PhD; Pedro Pérez Segura, MD, PhD; Jose Luis Rodriguez Peralto, MD, PhD; Xavier Solé, PhD; Ruth Vera, MD, PhD; Ana Vivancos, MD, PhD; Paula Gratal, MD, Teresa Pardo, MSc; Alvaro Rogado, MBA; Carlos Camps, MD, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>80</td>
<td>Ahmed Abdelhakeem, MD, Baptist Hospitals of Southeast Texas</td>
<td>Impact of Socioeconomic Status on Cancer Care in Southeast Texas: A Population-based Cohort Study</td>
<td>Jacob Thompson, MS, Junaid Anwar, MD; Telice Terro, RN, OCN; Maryam Vaseli, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>81</td>
<td>Brooke Leon, BA, Cardinal Health Inc</td>
<td>Community Oncologists’ Perceptions on the Evolving Role of Surrogate Endpoints in Oncologic Clinical Trials</td>
<td>Robert N. Bone, PhD; Yolaine Jeune-Smith, PhD; Bruce Feinberg, DO</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>82</td>
<td>Arjun Pon Avudaiappan, MD, Miami Cancer Institute</td>
<td>Evaluation of the Reliability of mpMRI in Diagnosing Prostate Cancer Following Intravesical Bacillus Calmette Guerin Therapy for Bladder Cancer</td>
<td>Pushan Prabhakar, MD; Surya Chundru, MD; Andrew Renshaw, MD; Ahmed Eldelfawy, MD; Jorge Caso, MD; Murugesan Manoharan, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>83</td>
<td>Marina Aweeda, BS, Vanderbilt-Ingram Cancer Center NCCN Member Institution</td>
<td>Reimagining the Pathology Report: Virtual 3D Specimen Mapping in Oncologic Surgery</td>
<td>Carly Fassler, BS; Yuna Chung, HS; Luyi Huang, HS; Spencer Yueh, BS; Joshua M. Lawrenz, MD; James S. Lewis, MD; Michael C. Topf, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>84</td>
<td>David Wei, PhD, Novartis Pharmaceuticals Corporation</td>
<td>Patient-Reported Outcome Measures Used In Patients With Chronic Phase-Chronic Myeloid Leukemia: A Systematic Review Of The Literature</td>
<td>Lovneet Saini; Aditi Kataria; Kejal Jadhav, MS Daisy Yang, PharmD; David Wei, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>85</td>
<td>Cesar Simbaqueva Clavijo, MD, MPH, The University of Texas MD Anderson Cancer Center NCCN Member Institution</td>
<td>Cemiplimab Use in Advanced Cutaneous Squamous Cell Carcinoma and Non-small Cell Lung Cancer - Risk Factors Associated with Mortality</td>
<td>Mehmet Altan, MD; Maria Franco-Vega, MD; Melvin Rivera, PharmD; Anisha Patel, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>86</td>
<td>Ayobami Olafimihan, MD, John H. Stroger Jr. Hospital of Cook County</td>
<td>Disparities in Colorectal Cancer Mortality Outcomes: A Ten Year Trend Study</td>
<td>Inimfon Jackson, MD, MPH, PhD; Stanley Ozogbo, MD, MPH, Jeremiah Bello, MD; Praise Faweihimin, BSc; Hafeez Shaka, MD; Michael Mullane, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>87</td>
<td>Teresa Pardo, BSc, MSc, Fundación ECO</td>
<td>Quality Recommendations for the Management of Cutaneous Squamous Cell Carcinoma (CSCC)</td>
<td>Javier Cañete Alvarez, MD, PhD; Josep Oriol Bermejo Segui, MD, PhD; Almudena Garcia Castaño Garcia; Castaño, MD, PhD; Vanessa Gabriela Jervis Gáza, MD, PhD; Ana Maria López López, MD, PhD; Susana Piñi Sarandi, MD, PhD; Ondine Sammartin Jiménez, MD, PhD; Ainara Soria Rivas, MD, PhD; Paula Gratal, PhD; Teresa Pardo, MSc; Alvaro Rogado, MBA; Alfonso Berrocal, MD, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>88</td>
<td>Arjuhn R., MD Madras Medical College and Research Institute: Madras Medical College and Government General Hospital</td>
<td>Hippocampal Optimization and Dosimetric Analysis on Feasibility of Hippocampal Sparing in Primary Gliomas: A Retrospective Dosimetric Study in a Tertiary Care Centre</td>
<td>Jeeva S., MBBS, MDRT; Vijayasree T. N., MBBS, MDRT</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>89</td>
<td>Rose Chang, ScD Merck &amp; Co Inc.</td>
<td>Real-world Treatment Patterns of Selumetinib Among Patients with Neurofibromatosis Type I and Plexiform Neurofibroma in the United States</td>
<td>Rose Chang, ScD; Theresa Dettling, MPH; Raj Desai, PhD; Chi Gao, ScD; Azeem Banatwalla, BS; Sydney Ng, MPH; Sama Ahsan, MD; Mei Sheng Duh, ScD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>90</td>
<td>Shyamala Navada, MD Geron Corporation</td>
<td>Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data</td>
<td>Nishan Sengupta, PhD; Dylan Supina, PhD; Shyamala Navada, MD; Revi Potkin, B. Tech; Rohit Tyagi, MPH; Timothy Werwath, MS; Zhouer Xie, MD; Eric Padron, MD; David Sallman, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>91</td>
<td>Junaid Anwar, MD Baptist Hospitals of Southeast Texas</td>
<td>Efficacy of Selinexor in Acute Myeloid Leukemia: A Systematic Review and Metaanalysis</td>
<td>Muhammad Haseeb, MD; Anusha Baddam, MBBS; Salma Saidahmed, MBBS; Binayak Singh, MBBS; Roshan NA, MBBS; Zahoor Ahmed, MBBS; Ahmed Abdelakeem, MD; Kachhadia Meet, MBBS; Raza Zarrar, MD; Tahir Naqvi, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>92</td>
<td>Brenda Santellano, MD Augusta University</td>
<td>The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review of Literature</td>
<td>Rashi Agrawal, MS; Gabriela Duchesne, MS; Muhannad Sharara, MD; E. Andrew Balas, MD, PhD; Gagan Agrawal, PhD; Meng-Han Tsai, PhD; Asha Nayak-Kapoor, MD; Jorge E. Cortes, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>93</td>
<td>Jessica Neeb, MSN, RN, OCN The US Oncology Network</td>
<td>Place of Death from Cancer in Episodic Value Based Care Models in a Community Oncology Network</td>
<td>Lalan Wilfong, MD; Sharon Hart, CMHP; Hope Ives, BS; Jessica Neeb, MSN, RN, OCN</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>94</td>
<td>Amanda Watson, BHSc Lymphoma Coalition</td>
<td>Predicting Treatment Related Fatigue in the Context of Lymphoma and Chronic Lymphocytic Leukemia</td>
<td>Amanda Watson, BHSc; Shawn Sajkowski, BA; Natacha Bolaños; Lorna Warwick, BA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>95</td>
<td>Sierra Washington, MPH Moffitt Cancer Center NCCN Member Institution</td>
<td>Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers: Trial in Progress</td>
<td>Sofia Fonseca, BA; Valerie Yeepez, MMS; Karen Brandon, PhD; Bob Gore, PhD; Min-Jang Yang, PhD; Sarah Jones, BA; Ranjita Poudel, PhD; Majia Reblin, PhD; Heather Jim, PhD; Joseph Pidala, MD; PhD Christine Venci, PhD</td>
<td>Trials in Progress</td>
</tr>
<tr>
<td>96</td>
<td>Rima Nakrani, MD, MSc Fox Chase Cancer Center NCCN Member Institution</td>
<td>A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Refractory Gastric Cancer Patients</td>
<td>Tanu Singh, MS, PhD; Elizabeth Handorf, PhD; Katherine R. Alpaugh, PhD; Namrita Vijayvergia, MD</td>
<td>Trials in Progress</td>
</tr>
<tr>
<td>97</td>
<td>Norman LaFrance, MD PLUS Therapeutics</td>
<td>Rheinmun (RE-186) Obisbemeda (RE-186 nanoliposome [186RNL]) in Leptomeningeal Metastasis (LM) Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility Through Cohorts 1-4</td>
<td>Andrew Brenner, MD; Priya Kunthekar, MD; Michael Youssuf, MD; Ande Bao, PhD; Melissa Moore, PhD; Joel Michalek, PhD; Marc Hedrick, MD; William Phillips, MD; Toral Patel, MD; Jeffrey Weinberg, MD; John Floyd, MD</td>
<td>Trials in Progress</td>
</tr>
<tr>
<td>98</td>
<td>Airat Garifullin, MD P. A. Herzen Moscow Research Oncology Institute</td>
<td>Revolutionizing NO Therapy: Novel NO Generator Enhances Quality of Life and Cardiopulmonary Function in Lung Cancer Patients</td>
<td>Peter Shegay, Dr; Oleg Aleksandrov, Dr; Oleg Pikin, Dr; Andrey Ryabov, Dr; Airat Garifullin, MD</td>
<td>Trials in Progress</td>
</tr>
<tr>
<td>99</td>
<td>Vandana Dhingra, DNB All India Institute of Medical Sciences - Rishikesh</td>
<td>Role of [99m Tc] DTPA-bis(Choline) in Evaluation of Breast Cancer: A Prospective Diagnostic Trial in Progress at AIIMS Rishikesh</td>
<td>Vandana Dhingra, DNB; Puja P. Hazari, PhD; Shranav Jha, MD; Sanjith L S, MD</td>
<td>Trials in Progress</td>
</tr>
</tbody>
</table>
# General Poster Session II

Hosted by NCCN Oncology Research Program (ORP)

Session II  Saturday, April 6

Breakfast 7:30 - 8:30 AM | Morning Break 9:45 - 10:05 AM

Lunch 11:55 AM - 1:10 PM | Afternoon Break 3:00 - 3:30 PM

## Presenting Author and Institution | Title | Co-Authors | Category
---|---|---|---
100 | Adrianna Craigat, BS Moffitt Cancer Center NCCN Member Institution | Improved Access through an Integrated Supportive Care Model Reduced Urgent Care Referral and Admission Rates for Patients with Gastrointestinal Malignancy | Nicole Nardella, MS, BS; Dena Berhan, BS; Denny Lu, HS; Sarah Goodchild, BS; Terry Gruchow, PA-C, MHS; DRAAPY; Young Chang, MD; Sahana Rajasekhara, MD; Pamela Hodul, MD | Outcomes and Health Services Research

101 | Alexandrina Balanean, MPH Cardinal Health Inc | Comparing Apples to Apples in Uterine Cancer: Racial Disparity and Propensity Score Matching | Yolaine Jeune-Smith, PhD; Parisa Asgarisabet, PhD; Camryn Craig, BS; Harlen Hays, MPH; Jalayna Laney, RN; Ajeet Gajra, MBBS, FACP; Bruce Feinberg, DO | Outcomes and Health Services Research

102 | Danielle Brabender, MD University of Southern California Keck School of Medicine | The Clinical Effect of a Community-Based Genetic Testing Program | Emily Siegel, MD; Julie Culver, MS; Jacob Comeaux, MG; Arral Date, MD; Amanda Woodward, MD | Epidemiology/Risks/Prevention

103 | Yazan Madanat, MD UT Southwestern Simmons Comprehensive Cancer Center NCCN Member Institution | Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/ineligible for Erythropoiesis Stimulating Agents (ESAs) | Michael R. Savona, MD; Mikkael A. Sekeres, MD; Uwe Platzbecker, MD; Valeria Santini, MD; Pierre Fenaux, MD; PhD; Maria Diaz-Campelo, MD, PhD; David Volcik, MD, PhD; Tymara Berry, MD; Souria Dougherty, MBA; Sheetal Shah, BA; Libo Sun, PhD; Ying Wan, MD; PhD; Fei Huang, PhD; Shyamala Navada, MD; Rami S. Komrokji, MD; Amer M. Zeidan, MBBS, MHS | Clinical Oncology

104 | Xiaohan Hu, PhD, MPH Merck & Co Inc | Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients with Resected Non-Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023 | Yu-Han Kao, PhD; Ashwini Arunachalam, MPH, B.D.S.; Diana Chirovsky, PhD; Yiru Wang, PhD; Chenan Zhang, MS, PhD; Kaitlyn Kane, MS; Ayman Samkari, MD | Outcomes and Health Services Research

105 | Derek W. Ren, BS UCLA Jonsson Comprehensive Cancer Center NCCN Member Institution | Improving Anal Cancer Screening: A Comparative Analysis of High-Risk Human Papillomavirus Tests, Alone or in Combination with Anal Cytology Assays, to Predict High-Grade Squamous Intraepithelial Lesions | Hilary K. Hsu, PhD; Jenny Brook, MS; Gypsamber D'Souza, PhD; Jian Yu Rao, MD; Todd Brown, MD; Matt Moran, MSN, ANP-BC; Frank J. Jenkens, MD; Enestro Rodriguez, MSN; David Elashoff, PhD; Stephen Young, PhD; Nancy Jooste, MD; Robert K. Bolan, MD; Seongmeen Kim, BSN; Susheel Reddy, MPH; Elizabeth Chiao, MD, MPH; Elizabeth Stier, MD; Dorothy Wiley, PhD | Epidemiology/Risks/Prevention

106 | Nitya Batra, MBBS Corewell Health William Beaumont University Hospital | Myeloid Sarcoma in a Patient with Marfan Syndrome | Atulya Aman Khosha, MBBS; Shyam Poudel, MD; Daniel Ezekrudo, MD, PhD | Clinical Oncology

107 | Guy Shechter, PhD, MBA MedTech Analytics, LLC | Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer | David Morrell, MBA; Regina Grebla, PhD; Steven Vemino, MD, PhD | Outcomes and Health Services Research

108 | Caitlin Finelli, DO South Pointe Hospital | Evaluating and Improving Post-Operative VTE Prophylaxis in Patients with a History of Cancer: Results of a Quality Improvement Initiative in a Community Hospital Setting | Kristen Conrad-Schnetz, DO; Tasha Bandiera, MSSA, LISW-S, AMC-SW | Best Practices in Implementation and Use of Clinical Practice Guidelines

109 | Thakshila Liyanage, PhD Early Is Good, Inc. | A Cost Effective, Noninvasive Multimomics Assay (BCDx) for Diagnostic Accuracy of Bladder Cancer Compares to the Gold Standard of Cytoscopy and Cytology | Asel Habarakada Liyanage, MSc | Quality Improvement

110 | Keisuke Otani, MD, PhD Dana-Farber/Brigham and Women's Cancer Center | Impact of Somatic Mutations on Outcomes of Salvage Radiation and Hormonal Therapy for Prostate Cancer Recurrence After Prostatectomy | David J. Konieczkowski, MD, PhD; Daniel J. Rodden, BA; Shinuk Wu, MD; Elai Davicioni, PhD; Philip J. Taylor, MD; Douglas M. Dahl, MD; Chin-Lee Wu, MD, PhD; Sophia C. Kamran, MD; Jason A. Elshatnawi, MD, PhD; David T. Miyamoto, MD, PhD | Correlative/Genomic

111 | Xiaohui Chen, MD, PhD Fujian Medical University | Epigenetic Analysis on RUNX3 Mislocalization and Its Association with Tumor Microenvironment Alteration in Non-small Cell Lung Cancer | Chuanzhong Huang, PhD; Yi Shi, PhD; Jianping Lu, MD; Xiaohui Chen, MD; Weilin Liu, MD | Correlative/Genomic

Follow the Expert Guided Poster Tour

Open to all attendees. No pre-registration required. Experts from NCCN Member Institutions will lead a group of conference attendees and highlight research. Meet by the Posters in the Exhibit Hall at 12:25 PM.
<table>
<thead>
<tr>
<th>#</th>
<th>Presenting Author and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>112</td>
<td>Carly McCain, BS, BSN Northside Hospital Atlanta</td>
<td>Reporting the False Negative Rate of Sentinel Lymph Node Biopsy for Melanoma. SLNBI: a Useful Quality Control Metric</td>
<td>Janice Bone, BS, Mildred Jones, BA, Nicole Kounalakisd, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>113</td>
<td>Amy F. Ballou, DNP University of South Carolina</td>
<td>Characteristics of Individuals with Early-Onset GI Cancers in the Southeastern US</td>
<td>Abbas S. Tavakoli, DrPH, MPH, ME, Karen E. Wickersham, PhD, RN</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>114</td>
<td>Brooke Dulka, PhD Cardinal Health Inc.</td>
<td>Perceptions of CARITATITUDE-4 for Patients With Relapsed/Refractory Multiple Myeloma</td>
<td>Luke Jennings-Zhang, PharmD; Samuel Baird, MPH; Robert N. Bone, PhD; Yolane Jeune-Smith, PharmD; Muhamed Baljevic, MD; Bruce Feinberg, DO</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>115</td>
<td>Yasmin Katzmann Watson Clinic LLP</td>
<td>Monitoring Concordance of Chronic Lymphocytic Leukemia (CLL) at Watson Clinic LLP: Diagnosis &amp; Treatment</td>
<td>Shalini Mulaparthi, MD, Noreen McGowan, RN, BSN, CCRC</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>116</td>
<td>Emily Nash Smyth, PharmD Eli Lilly and Company</td>
<td>Real-world Treatment (tx) Patterns and Outcomes for First-Line (1L) Novel Hormonal Agent (NHA) Naive Metastatic Castration Resistant Prostate Cancer (mCRPC) Including in Black and/or African American (BAA) Patients (Pts)</td>
<td>Samuel Whipple, MSPH; Mark Guinter, PhD; Nadine Haddad, PhD; Wenxian Piao, PhD; Zhanglin Ci, PhD; Arjun Babar, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>117</td>
<td>Jerry Kenmoe, MD McLaren Flint Hospital</td>
<td>Re-evaluating Breast Cancer Screening Recommendations: An Analysis of Breast Cancer Incidence by Age groups</td>
<td>Calvin Gihmire, MD; Harmeet Ghummam, MD; Jones Kenmoe, MD; Tejaswi Vinjam, MD; Arvind Kunadi, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>118</td>
<td>Ronscardy Mondesir, BA Miami Cancer Institute</td>
<td>Length of Hospital Stay, Unplanned Readmission and Mortality for Patients Treated with Partial Nephrectomy or Radical Nephrectomy for Stage I and II Kidney Tumors</td>
<td>Daniel Boaretto, BS; Nathan VanderVeer-Harris, BS; Dianelles Gonzalez Pupo, BA; Pushan Prabhakar, MBBS; Arjun Pon Auvdiaipapan, MS, MCh; Ahmad Eldrefawy, MD; Murugesan Manoharan, MD; Jorge Caso, MD; Ronscardy Mondesir, BA</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>119</td>
<td>David Wei, PhD Novartis Pharmaceuticals Corporation</td>
<td>Non-optimal Treatment in Early Line Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI): A Claims Data Analysis</td>
<td>David Wei, PhD; Daisy Yang, PharmD; Hela Romdhanli, PhD; Dominick Latremouille-Viau, MA; Annie Guzman; MSc; Kejal JadHAV, MSc</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>120</td>
<td>Pushan Prabhakar, MBBS Miami Cancer Institute</td>
<td>Surgeon Administered Transversus Abdominis Plane Block with Local Anesthetic Infiltration Versus Transversus Abdominis Plane Block Following Robot-Assisted Radical Prostatectomy</td>
<td>Arjun Pon Auvdiaipapan, MS, MCh; Daniel Ajabshr, BS; Orlando Brito Martinez, MD; Ahmad Eldrefawy, MD; Jorge Caso, MD; Murugesan Manoharan, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>121</td>
<td>Michael Imeh, MBBS Lincoln Medical Center</td>
<td>Impact of Futility on Hospital Outcomes Among Patients with Hemophagocytic Lymphohistiocytosis Who Received Autologous Stem Cell Transplantation in the United States</td>
<td>Ani Gvajaia, MD; Chukwunonye Amaesi, MBBS; Chiamaka Nwachukwu, MBBS; Fidelis Uwumiro, MBBS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>122</td>
<td>Ayobami Olafimihan, MD John H. Stroger Jr. Hospital of Cook County</td>
<td>Trends in the Incidence and Mortality of Metastatic Epiperal Spinal Cord Compression: A Ten-Year Population-Based Study</td>
<td>Inimfon Jackson, MD, MPH, PhD; Stanley Ozogbo, MD, MPH; Jeremiah Bello, MD; Praise Fawehinmi, BSc; Hafeez Shaka, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>123</td>
<td>Edward Li, PharmD, MPH Sandiz Inc.</td>
<td>Chemotherapy-Induced Febrile Neutropenia (FN) in the US: Healthcare Resource Utilization (HCRU) and Costs</td>
<td>Marie Yasuda, PharmD, MS; Jeanine Flanigan, PharmD, MS; Chi-Chang Chen, MS/Pharm, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>124</td>
<td>Lisa Tesoriero, MSN Memorial Sloan Kettering Cancer Center NCDN Member Institution</td>
<td>Standardizing Height and Weight Measurement for Treatment Calculations in Adult Patients with Cancer</td>
<td>Elizabeth Rodriguez, DNP; MaryAnn Connor, MSN; Jericho Garcia, MSN; Tiffany Lin, MPH; Mark Robson, MD; Tiffany Jan, MD; Karen Collum, DNP</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>125</td>
<td>Ana M. Barragan, MD, PhD Universidad Del Rosario</td>
<td>Serum Pepsinogen I (Ig) in Patients Undergoing Esophagogastroduodenoscopy and Biopsy in Two Institutions in Bogotá, Colombia</td>
<td>Andres Isaza-Restrepo, MD, MSc; Geovann Hernandez-Celi, MD; Viviana Marcela Hidalgo-Mora, MD; Joon-Kung Whang, MD; Danna Lesley Cruz Reyes, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>126</td>
<td>Yanal Alimner, MD, MPH Markey Cancer Center</td>
<td>The Effect of TBI Based Conditioning Regimen on Recurrence and Transplant Related Mortality Among Patients with Mantle Cell Lymphoma who Received Autologous Bone Marrow Transplant</td>
<td>Feviz F. Yalin, MD, Chahtanara Iravagapuru, MD; Redhma Ramial, MD; Reinhold Munker, MD; Ayman Qasrawi, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>127</td>
<td>Lindsey Behlen Cotton, DO, MS DELFI Diagnostics</td>
<td>Utilizing Diverse Enrollment to Validate the DELFI Fragmentsome Test for Advancing Lung Cancer Screening</td>
<td>Peter B. Bach, MD; Caitlin A Schonewell, MD, MS; Demetria Tennesfoss, DNP; Niti Trivedi, MPH; Chris Cisar, BS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>128</td>
<td>Jason Alter, PhD Exosome Diagnostics</td>
<td>Prostate Biopsies Against Medical Advice: Unveiling New Biomarker Insights for Men</td>
<td>Sonia Kumar, PhD; Johan Skog, PhD; Vinita Verma, MPH; Kyle Schimizzi, BS; Yuiyan Yao, MS; Christian J. Ray, PhD; Brian Haynes, PhD; Ronald Tutrone, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>129</td>
<td>Shradha Parmeswaran, MBBS, MD Madras Medical College</td>
<td>Pleura brachialis A Dosimetric Study in Carcinoma Head and Neck Treated Using Conformal Radiotherapy</td>
<td>Jyothish K.C., MBBS MDRT; Jeesta S., MBBS MDRT</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----</td>
<td>-----------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>130</td>
<td>John Kelvin Lalusis, MD</td>
<td>Necoadjuvant Tyrosine Kinase Inhibitors (TKIs) Efficacy in EGFR Positive Stage III Nonsmall Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis</td>
<td>John Lois Padayao, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>131</td>
<td>Elizabeth Marrett, MPH</td>
<td>Determinants of Quality of Life and Optimism in Patients with EGFR Mutated Advanced Non-small Cell Lung Cancer</td>
<td>Salerno Gupta, MS; Kushal Modi, MS; Song Li, PhD; Jillian Rowe, BA; Jackie Kwong, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>132</td>
<td>Krishna Desai, MD</td>
<td>Epidemiological and Survival Analysis of Hemangiopericytoma in the Last Twenty Years</td>
<td>Yu Yu Thar, MD; Sabah Iqbal, MD; Manzoor Rather, MD; Rajesh Thirumaran, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>133</td>
<td>Jiping Chen, RN</td>
<td>Evaluation of Aromatherapy with Lavender Oil During the Perioperative Period of Benign Prostate Hyperplasia: A Randomized Placebo Controlled Clinical Observation</td>
<td>Lijun Tang, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>134</td>
<td>Grace Allen, MSN, OCN</td>
<td>Improving Adherence to Safe Handling of Oral Hazardous Drugs and Contaminated Wastes Guidelines</td>
<td>Grace Allen, MSN, OCN; Sadeeka Al-Majid, PhD, RN</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>135</td>
<td>Erica Fortune, PhD</td>
<td>Patient Experiences and Perceptions of Biomarker Testing in AML and CML: A Qualitative Analysis</td>
<td>Abigail Newell, PhD; Maria Gonzalez, MS; Madyson Popalis, MPH; Elif Andac-Jones, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>136</td>
<td>Aylin Yucel, PhD</td>
<td>Value of Early Transfusion Burden Reduction in Lower-Risk Myelodysplastic Syndromes (LR-MDS)</td>
<td>Sven L Klijn, MSc; Hong Xiao, PhD; Benjamin White, MSc; Conrado Franco-Villalobos, MSc; Alina Sichevaya, BA; Ahmed Hnoosh, MSc; Dimana Miteva, PhD; Aylin Yucel, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>137</td>
<td>Sakidhat Saowapa, MD</td>
<td>Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis</td>
<td>Natchaya Polpichai, MD; Pharat Siladech, MD; Carlotta Wannaphut, MD; Masanawa Tanariyakul, MD; Phuwxawitch Wattanachayakul, MD; Pakin Laiwiri, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>138</td>
<td>Dominique Lopez, BS</td>
<td>Partial versus Radical Nephrectomy: An Age-Wise Comparison of the National Cancer Database</td>
<td>Daniel Boaretto, BS; Armin Ghomeshi, BS; Dominique Lopez, BS; Pushan Prabhakar, MBBS; Arjun Pon Avudaiappan, MS, MCh; Ahmed Eldefrawy, MD; Munusaran Manoharan, MD; Jorge Caso, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>139</td>
<td>Chi-Yin Liao, PhD</td>
<td>Intentional Weight Loss and Associated Cancer Incidence Among Patients With Overweight or Obesity: A Systematic Literature Review</td>
<td>Kristin M. Sheffield, PhD; Meredith M. Hoog, MPH; David Schapiro, PharmD; Raghurav Keri, PhD; Wambui Grace Gathiri-Mwangi, PhD; Hong Kan, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>140</td>
<td>Insiia Ilyas Selene, MD</td>
<td>Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Immunotherapy: An Analysis of the National Cancer Database (NCDB)</td>
<td>Sven L Klijn, MSc; Hong Xiao, PhD; Benjamin White, MSc; Conrado Franco-Villalobos, MSc; Alina Sichevaya, BA; Ahmed Hnoosh, MSc; Dimana Miteva, PhD; Aylin Yucel, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>141</td>
<td>Saroj Prasad Sah, MS</td>
<td>Oncological Outcome of Multimodality Treatment in Ewing Sarcoma</td>
<td>N/A</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>142</td>
<td>Ruixuan Jiang, PharmD, PhD</td>
<td>Real-World Clinical Outcomes in Patients With Advanced/Metastatic Melanoma and Brain Metastases Treated With Pembrolizumab Monotherapy – An Analysis of the ADROReg German Skin Cancer Registry</td>
<td>Michael Weichenthal, MD, PhD; Cesar I. Fernandez-Lazzaro, PhD, MPH, PharmD; Anja Rudolph, MSc, PhD; Clemens Krepler, MD; Peter Mohr, MD, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>143</td>
<td>Ilene Trinh, BS</td>
<td>Analysis of Risk of Bone Fracture and Osteoporosis and Dual-Energy X Ray Absorptiometry Screening Rates in Lung Cancer Survivors with and without Bone Metastases</td>
<td>Jaime Abraham Perez, PhD; Ellesper Harper, BS; Lauren Chiee, MD; Qian Wang, MD, MPH; Melinda Hsu, MD, MS</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>144</td>
<td>Harneet Ghumman, MD</td>
<td>A Comprehensive Examination of Disparities in Metastatic Breast Cancer Incidence: Race, Income and Geography</td>
<td>Calvin Ghimire, MD; Harneet Ghumman, MD; Elizabeth Mikhail, MD; Lones Kemoe, BS; Arvind Kunadi, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>145</td>
<td>Charlotte Ezraty, MD</td>
<td>Treatment Implications of Expanded Genetic Testing Guidelines for Patients with Breast Cancer: A Retrospective Quality Review</td>
<td>Alaina Kessler, MD, MPH; Paula Klein, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>146</td>
<td>Megan Adams</td>
<td>A Narrative Review on Geriatric Assessment and Outcomes in Diffuse Large B-cell Lymphoma: Differentiating Frail, frail, and unfit Patients</td>
<td>Iulia Kovalenko, MD; Chandli Garg, MD; Megan Adams; Pam G. Khosla, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>147</td>
<td>Nicolas Felipe Camargo, MD</td>
<td>Characterization of Short-Term Surgical Outcomes in Laparoscopic Gastroctomy at a High-Volume Center in Latin America: 10 Years of Experience</td>
<td>Jorge Isaac Vargas, MD; Lilianna Maria Suarez Olarte, MD; German Jimenez, MD; Raúl Enrique Guevara, MD; Wilmar Martín, MD; Nicolás Felipe Camargo, MD; Eduardo Espin Lanz, MD; Francisco Solano Perdomo, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>148</td>
<td>Elliane Vieira, BSN, RN-BC, OCN</td>
<td>Temporary Toilet Lids Minimize Contamination of Bathroom Surfaces with Hazardous Drugs</td>
<td>Grace Allen, MSN, OCN; Sadeeka Al-Majid, PhD, RN, FAAN</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>149</td>
<td>Tomer Bar Noy, MD</td>
<td>Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Endometrial Intraepithelial Neoplasia Undergoing Robotic Surgery</td>
<td>Yossi Tzur, MD; Yoav Brezinov, MD; Emad Matanes, MD; Susie Lau, MD; Shannon Salvador, MD; Melica Nourmoussavi, Brodeur, MD; MSc; Walter Gottlieb, MD, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>150</td>
<td>Brenda Patricia Garza Badillo, MD</td>
<td>Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico</td>
<td>David Hernández Barajas, MD; José Luis González Vela, MD; Ileana Cecilia Reynosa Silva, MD; Luis Andrés González Torres, MD; Ana Patricia Sánchez Fonseca, MS</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>151</td>
<td>Jennifer Browning, MS, APRN-CNP, ACHPN</td>
<td>Implementation of Therapeutic Touch in an Ambulatory Palliative Oncology Clinic</td>
<td>Janine Overcash, PhD, APRN-CNP, FAANP, FAAN; Robin Rosselet, DNP, APRN-CNP/CNS, AOCN; Diane Von Ah, PhD, RN, FAAN</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>152</td>
<td>Patricia Elizabeth Litkowski, MD</td>
<td>Retrospective Analysis of 30-day Readmission Risk in Oncology Patients</td>
<td>Ningying Wu, MD, PhD; Lauren Jurkowski, MD; Yash Shah, MD; Anna McCormas, RN, BSN; Olivia Aranha, MD, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>153</td>
<td>Jennifer Fernandez</td>
<td>The Impact of Prescription Drug Plan (Part D) Enrollment for Medicare Beneficiaries on Eligibility for Episode-Based Care Model Participation and Total Cost of Care (TCOC) at a Community Oncology Network</td>
<td>John Albaugh; Lora Markley, Pnuneth Indural: Lalani Wilfong, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>154</td>
<td>Taylor Baggarley BSN, RN, CBCN, OCN</td>
<td>Administration of Goserelin at Alternative Anatomical Sites in Premenopausal Breast Cancer Patients</td>
<td>Nikhil Manjunath, MD; Stacia Young, PharmD, MBA; Joan Cannon, PharmD, MBA; Taylor Baggarley, RN</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>155</td>
<td>Puneeth Indural, MD, MS, MBBS</td>
<td>Novel Therapies in the Oncology Care Model: A Profile in Review</td>
<td>Lalan S. Wilfong, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>156</td>
<td>Chalothorn Wannaphut, MD</td>
<td>The Role of Obesity in Influencing Patient Survival in Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy: A Systematic Review and Meta-analysis</td>
<td>Sakidatad Saoswapa, MD; Natchaya Polpichai, MD; Pharit Siladech, MD; Manasawee Tananyakul, MD; Phuuxudith Wattanachayakul, MD, Pakin Lalitmithi, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>158</td>
<td>Cho Han Chang, MD, MMSc</td>
<td>The Effect of Exercise on Cardiotoxicity in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Systematic Review and Meta-analysis</td>
<td>Yu-Cheng Chang, MD; Yulin Haw, MD; Jia Yi Tan, MD; Cho-Haen Chang, MD; Yuan Ping Hsia, MD; Cho-Hung Chang, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>159</td>
<td>Dhauna Karam Prasad, MBBS, MS</td>
<td>Prevalence of Anxiety and Depression in Newly-Diagnosed Breast Cancer Patients in Rural Minnesota</td>
<td>Mina Hanna, MD; Timothy F. Kozelsky, MD; Scott H. Okuno, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>160</td>
<td>Insoo Ilyas Selene, MD</td>
<td>Association Between Primary Tumor Size and Prognosis in Concomitant Metastatic Renal Cell Carcinoma in Patients Who Underwent First Line Immunotherapy-based Therapy: A Real World Data Analysis</td>
<td>Roshimta Bardhan, DO; Rani Jayawal, Amina Dhahari, MD; Jennifer C. Torres Yee, MD; Heidi L. Weiss, PhD; Zin Myint, MD; Kimberly D. Ratiff</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>161</td>
<td>Derek Tang, PhD, MS</td>
<td>Real World (RWH) Effectiveness of Erythropoiesis-Stimulating Agents (ESAs) after Luspatercept in Patients (pts) with Myelodysplastic Syndromes (MDS): A Retrospective Analysis of a Large Healthcare Claims Database in the United States</td>
<td>Rui Song, PhD; Samantha Staff, MS; Enrico Zanardo, PhD; Lynn Huyh, MPH, MBA, DrPh; Manasi Mohan, MS; Megan Pinaire, MPH; Derek Tang, PhD, MS; Mihran Yenikomshian, MBA; Victoria Barghout, MSPH; Adeola Y. Makinde, PhD; Khashypat Patel, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>162</td>
<td>Cheongin Im, MSN, RN</td>
<td>Mobile Health (mHealth) Interventions for Colorectal Cancer (CRC) Survivors: A Systematic Review</td>
<td>Megan C. Thomas Hebdon, PhD, DNP, RN, NP-C; Narnuam E.Clifford, MSN, RN, FNP; Carolyn Phillips, PhD, MSN, RN, AOCNP</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>163</td>
<td>Lynn Abbott-Cloud, MA</td>
<td>Reaching Unmet Needs of Lung Cancer Patients Through Hope Totes and Educational Meetings</td>
<td>N/A</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>164</td>
<td>Ahmad Basharat, MD</td>
<td>Outcomes with Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis</td>
<td>Jawad Noor, MD; Muhammad Fareed Khalid, MD; Muhammad Kashiqim Amin, MD; Mehnaz Nadeem, MD; Ahmad Basharat, MD; Michael Jagalal, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>165</td>
<td>Moazzam Shahzad, MD</td>
<td>Outcomes with Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis</td>
<td>Jawad Noor, MD; Muhammad Fareed Khalid, MD; Muhammad Kashiqim Amin, MD; Mehnaz Nadeem, MD; Ahmad Basharat, MD; Michael Jagalal, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>-------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>166</td>
<td>Precious C. Ferguson, MSN, APRN, FNP-BC</td>
<td>Effects of a Music-Based Intervention on Reducing Compassion Fatigue in Oncology Advanced Practice Providers</td>
<td>N/A</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>167</td>
<td>Kimberly Younger, BSEE; BSBBME</td>
<td>Determining the Barriers to Colorectal Cancer in Patients with Positive Cologuard Test</td>
<td>Jacob Guernsey, Joseph W. LeMaster, MD, MPH; Daniel Parente, MD, PhD; Allen K. Green, MD, MPH; Jennifer L. Woodward, MD, MPH</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>168</td>
<td>Alexander Rabadi, MD</td>
<td>Casting Light on Metastatic Kidney Cancer Survival: A Gender-Based Examination</td>
<td>Calvin Ghimire, MD; Alexander Rabadi, MD; Anjela Shrestha, MD; Arvind Kunadi, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>169</td>
<td>Anjela Shrestha, MD</td>
<td>Unveiling the Socioeconomic Gradient: Income-Linked trends in metastatic Kidney Cancer Survival</td>
<td>Calvin Ghimire, MD; Alexander Rabadi, MD; Anjela Shrestha, MD; Arvind Kunadi, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>170</td>
<td>Nathaniel Veer-Harris, BS</td>
<td>A Propensity Matched Survival Analysis Comparing Partial Versus Radical Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: A National Cancer Database Study</td>
<td>Nathaniel Veer-Harris, BS, Aden Swayze, BA; Ronscardy Mondesire, BA; Raghuram Reddy, BS; Pushan Prabhatkar, MBBS; Arjun Poon Avudaiappan, MS, MCh; Ahmed Eldefrawy, MD; Muruganathan Manoharan, MD; Jorge Caso, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>171</td>
<td>Mohammed Bilal Elahi, MBBS, MS, FRCS</td>
<td>Outcome of Positron Emission Tomography –Computed Tomography Staging in Breast Cancer Patients Having Neo-adjuvant Systemic Therapy</td>
<td>Mohammed Bilal Elahi, MBBS, MS, FRCS; Naila Bint Isfan, MBBS, MS, FRCS; Dorin Dumitru, MBBS, MS, FRCS; Brennan Wooler, MBBS, FRCS; Peter Kneeshaw, MB, MB, FRCS; Karlke Grover, MBBS, MS, FRCS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>172</td>
<td>Athavar Sharma, BE</td>
<td>Empirical Study to Estimate Real World Impact of Delay in Adjunctive Treatment on Healthcare Resource Utilization and Cost Burden</td>
<td>Arunav Saxia, MS; Athavar Sharma, BE; Priyanka Halder, MBA; Manu Prasad, MBA; Prabhakar Gaut, B. Tech in Computer Science; Venkata Sai Sumanth Pulluri, B. Tech in Mechanical; Stuti Jha, B. Tech</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>173</td>
<td>Pritika Sharma, MBBS</td>
<td>Our Approach to Patient Selection for Polatuzumab-Based Therapy in Advanced Diffuse Large B-Cell Lymphoma</td>
<td>Sreshtha Paranjy, MD; Amir Steinberg, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>174</td>
<td>Aaron I. Kurian, MD</td>
<td>Evaluation of Framework for Colorectal Cancer Health Needs Assessment in North and Central Asian Countries</td>
<td>Rebecca Pratit, MD; Olga Santiago, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>175</td>
<td>Julia Olsen, MS</td>
<td>Standalone Performance Evaluation of an Artificial Intelligence Breast Cancer Detection Tool on Consecutively Collected Biopsy Proven Breast Cancer and Screening Negative Tomosynthesis Cases</td>
<td>Ashwini Kshirsagar, PhD; Julia Olsen, MS; Chirag Parthi, MD, MBA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>176</td>
<td>Catherine Boldig</td>
<td>Precision Medicine Drivers in Non-Small Cell Lung Cancer Brain Metastases</td>
<td>Kimberly Boldig, DO; Sepideh Mokhtari, MD; Arnold Etame, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>177</td>
<td>Aakash Tripathi, BS</td>
<td>Unifying Multimodal Data, Time Series Analytics, and Contextual Medical Memory: Introducing MINDS as an Oncology-Centric Cloud-Based Platform</td>
<td>Asim Waqas, MS; Ghulam Rasool, PhD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>178</td>
<td>Nikita Dahake, MD</td>
<td>Determining the Most Appropriate FIT to Increasing Colorectal Cancer Screening in the Community</td>
<td>Brianna Graham, MD; Gabrielle Gillow, MD; Shelby McNeilly, DD; Abraham Ifrah, MD; Manasa Vallabhaneni, MD; Christopher Grivas, MD; Rishab Khati, MD; Claire Raab, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>179</td>
<td>Charlotte Walmsley, MD</td>
<td>Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis in a Patient with Breast Cancer: A Case Report and Systematic Review of the Literature</td>
<td>Michael Anderssen Jr., MD; Barbara Lam, MD; Deepa Rangachari, MD; Shana Berwick, MD; Rushad Patell, MD</td>
<td>Case Reports</td>
</tr>
<tr>
<td>180</td>
<td>Carrie Sha, MD; Marie Liu, MD</td>
<td>Immunotherapy in Older Patients with Breast Cancer: Case Study and Literature Review</td>
<td>Marie Liu, MD; Diana Lake, MD; Jasmeet Singh, MD; Wanqing Iris Zhi, MD, PhD</td>
<td>Case Reports</td>
</tr>
<tr>
<td>181</td>
<td>Rachel Truong, MD</td>
<td>Liver-feeding on a Prayer: A Rare Case of Hepatocellular Carcinoma with Metastasis to the Thyroid</td>
<td>Odelys Graneta, DO; Shelby Piouche, MD; Alyssa Obermiller, DO; Van Anh T. Do, MD; Brian Shaw, DO; Jacqueline N. Kroff, DO</td>
<td>Case Reports</td>
</tr>
<tr>
<td>182</td>
<td>Aasif Alqam, MD</td>
<td>Navigating the Challenges of NUT Midline Carcinoma: A Case Study and Therapeutic Insights for an Aggressive Oncologic Entity</td>
<td>Phu V. Truong, MD, FACP</td>
<td>Case Reports</td>
</tr>
<tr>
<td>183</td>
<td>Myoungsuk Kim, PhD</td>
<td>Effects of Web-based Interventions on Quality of Life Among Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials</td>
<td>Myoungsuk Kim, PhD</td>
<td>Case Reports</td>
</tr>
<tr>
<td>184</td>
<td>John Sharp, MD</td>
<td>Response to Dabrafenib and Trametinib in a Patient with an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer</td>
<td>Daniel Jones, MD, PhD; Julia Rotow, MD; Panos Fidas, MD; Erin Berino, MD; Dwight Owen, MD, MS</td>
<td>Case Reports</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| 185 | Keval Yerigeri, MD  
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute  
NCCN Member Institution | Hemochromatosis in an Adult Female with Previous Iron Deficiency Anemia on Iron Supplementation | N/A | Case Reports |
| 186 | Paridhi Ghai, MD  
Bridgeport Hospital | Unmasking the Unpredictable: Spontaneous Tumor Lysis Syndrome in Metastatic Breast Cancer – A Case Beyond Expectations | Amy Gates, MD | Case Reports |
| 187 | Sesha Sai Kanakamedala, MD  
University of Central Florida | Extraluminary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis | Sesha Sai Kanakamedala, MD; Sarah Tinsley, MD; Jamal Mohsin, MD | Case Reports |
| 188 | Christine Jane Kurian, MD  
Cooper University Health Care | Complete Remission of Microsatellite Instability-High (MSI-H) Oligometastatic Poorly Differentiated Colon Adenocarcinoma after a Single Dose of Immunotherapy | Danny Markabawi, MD | Case Reports |
| 189 | Albert Jang, MD  
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute  
NCCN Member Institution | Successful Management of Loco-regionally Advanced and Oligometastatic Urothelial Carcinoma with Pembrolizumab-based Induction Regimen Followed by Consolidative Radical Resection of the Primary Tumor: A Multi-institutional Case Series | N/A | Case Reports |
| 190 | Jorge Arche Prats, MD  
Clinica INDISA | Neuroendocrine Tumor of the Gallbladder: A Case Report and Literature Review | N/A | Case Reports |
| 191 | Macarena Stevenson Figueroa, MD  
Clínica Alemana de Santiago SA | Preoperative Assessment of Vulvar Melanoma Surgical Margins Using in Vivo RCM | Nelson Mauricio Lobos Guede, MD; Álex Castro Medina, MD; Macarena Stevenson Figueroa, MD | Case Reports |
| 192 | Natalia de la Puente Mota  
Hospital Universitario Lucus Augusti | Gluteal Metastasis of Intrahepatic Cholangiocarcinoma: Clinical Case and Literature Review | Yolanda Gómez Fandiño; Francisco Javier Anguita Ramos; María López López; Mariacaudia Ocharán Puell; Belén López Carnero; Jorge González Ramírez; Adriana Fernández García; José Conde Vales | Case Reports |
| 193 | Kevin Fitzpatrick O’Sullivan, MD  
Beth Israel Deaconess Medical Center | Microgranular Acute Promyelocytic Leukemia Presenting as Recurrent Stroke and Isolated Neutropenia | Rusad Patell, MD; Jason Freed, MD | Case Reports |
| 194 | Junqing Liu, PhD, MSW  
Merck and Co. | Social Determinants of Health in Real-World Evidence Studies of Early-Stage Cancer Care: A Systematic Literature Review | Andrew Osterland, PharmD, MS; Sarah Markt, ScD; MPH; Arthur Sillah, PhD; Esther Renee Smith-Howard, PhD, RN; Gregory Patton, MD; Kashif Froizvi, MD; Andrew Osterland, PharmD, MS | Case Reports |
| 195 | Julie Williamson, MD  
University of Utah Medical Center | A Rare Case of Immune Checkpoint Inhibitor Induced Seronegative Myasthenia Gravis | Meenu Singh, MD | Case Reports |
| 196 | Nirmala Ghimirey, DO  
Summa Health System - Akron Campus | Microangiopathic Hemolytic Anemia as the Presenting Manifestation of Metastatic Breast Cancer | Phuong Uyen Vo, DO; James Dibb, DO; Jordan Hatch, DO; Saneer Mahesh, MD | Case Reports |
| 197 | Khushboo Lakhatariya, MBBS  
Trumbull Regional Medical Center | Rare case of a Paraneoplastic Cerebellar Ataxia Secondary to a Retropertioneal Neuroendocrine Tumor of Unknown Origin | Fehmida Laxmidhar, MBBS; Mrunal Patel, MBBS | Case Reports |
| 198 | Aaron Charles Lobo, MD  
Bridgeport Hospital | Hyperfibrinolysis as the Primary Presenting Sign of Metastatic Prostate Cancer: A Diagnostic Challenge | Zeynep Busra Zengin, MD; Charles Kenworthy, MD, PhD; Ansh Sharda, MD, MPH | Case Reports |
| 199 | Mrunal Patel, MBBS  
Trumbull Memorial Hospital | Brown Fat Adipose Tissue (BAT) Activation Mimicking Lymphoma-Associated Lymphadenopathy | Fehmida Laxmidhar, MBBS; Khushboo Lakhatariya, MBBS; Rushin Patel, MD | Case Reports |
Save These Dates

2024 Annual Congress: Hematologic Malignancies
Friday, September 20 – Saturday, September 21, 2024
New York Marriott Marquis • New York, NY
NCCN.org/hem
Virtual attendance available

Annual Conference
March 28 - 30
2025
New location! Caribe Royale Orlando • Orlando, FL
Pre-Conference Program
NCCN 2025 Nursing Program: Advancing Oncology Nursing™
Thursday, March 27, 2025
NCCN.org/conference
Virtual attendance available
Learn about patient assistance and reimbursement programs available.

Search by:

• Cancer Type or Supportive Care Indication
• Drug Name
• Reimbursement Program

Access for FREE online or via the app!

NCCN.org/reimbursement
Help people living with cancer. You can provide support for FREE RESOURCES and INNOVATIONS IN ONCOLOGY RESEARCH.

NCCNFoundation.org/Donate

Crossroads4Hope
A NETWORK OF CANCER SUPPORT

Our network embraces all people touched by cancer - the diagnosed and their loved ones - empowering individuals to take control of their health through access to resources, and programs of support, education, wellbeing and hope.

MyGo2Support, 24/7 Digital Patient Support Mobile Platform
Individual & Group Support (Apoyo emocional)
Nutrition Programs (Educación de nutrición)
Mind & Body Classes (Clases de salud)
Financial Assistance (Asistencia financiera)

Educational Workshops (Programas educativos)
Support4Families (Apoyo para familias)
My Voice Matters: Treatment Decision Support (Herramientas de apoyo a decisiones)
Resources & Referrals (Recursos y referencias)

Closing the Cancer Care Gap.

Accepting caregiver and patient referrals nationwide.
3 Crossroads Drive, Bedminster, NJ 07921 | www.crossroads4hope.org | 908-658-5400
Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options.
NCCN Guidelines for Patients®

Access 70+ FREE cancer resources

- Acute Lymphoblastic Leukemia (adult)
- Acute Lymphoblastic Leukemia (pediatric)
- Acute Myeloid Leukemia
- Adolescent and Young Adult Cancer
- Adrenal Tumors
- Anal Cancer
- Anemia and Neutropenia: Low Red and White Blood Cell Counts
- Basal Cell Skin Cancer
- B-Cell Lymphomas: Diffuse Large B-Cell Lymphomas
- B-Cell Lymphomas: Follicular Lymphoma
- B-Cell Lymphomas: Mantle Cell Lymphoma
- B-Cell Lymphomas: Marginal Zone Lymphomas
- Bladder Cancer
- Blood Clots and Cancer
- Bone Cancer
- Brain Cancer: Gliomas
- Breast Cancer: DCIS Breast Cancer
- Breast Cancer: Inflammatory Breast Cancer
- Breast Cancer: Invasive Breast Cancer
- Breast Cancer: Metastatic Breast Cancer
- Breast Cancer Screening and Diagnosis
- Central Nervous System Cancers: Primary Central Nervous System Lymphoma
- Cervical Cancer
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Colon Cancer
- Colorectal Cancer Screening
- Distress During Cancer Care
- Esophageal Cancer
- Fatigue and Cancer
- Gallbladder and Bile Duct Cancers
- Gastrointestinal Stromal Tumors (GIST)
- Graft-Versus-Host Disease
- Head and Neck Cancers: Mouth Cancer
- Head and Neck Cancers: Nasopharyngeal Cancer
- Head and Neck Cancers: Throat Cancer
- Hodgkin Lymphoma
- Hodgkin Lymphoma in Children
- Immunotherapy Side Effects: CAR T-Cell Therapy
- Immunotherapy Side Effects: Immune Checkpoint Inhibitors
- Kidney Cancer
- Liver Cancer
- Lung Cancer Screening
- Malignant Pleural Mesothelioma
- Melanoma
- Multiple Myeloma
- Mycosis Fungoides/Sézary Syndrome
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasms
- Nausea and Vomiting
- Neuroendocrine Tumors
- Non-Small Cell Lung Cancer: Early and Locally Advanced
- Non-Small Cell Lung Cancer: Metastatic
- Ovarian Cancer
- Palliative Care
- Pancreatic Cancer
- Peripherally T-Cell Lymphoma
- Primary Cutaneous Lymphomas
- Prostate Cancer: Advanced Stage
- Prostate Cancer: Early Stage
- Rectal Cancer
- Small Cell Lung Cancer
- Soft Tissue Sarcoma
- Squamous Cell Skin Cancer
- Stomach Cancer
- Survivorship Care for Cancer-Related Late and Long-Term Effects
- Survivorship Care for Healthy Living
- Systemic Mastocytosis
- Thyroid Cancer
- Uterine Cancer
- Waldenström Macroglobulinemia

Free access
NCCN.org/patientguidelines
NCCN.org/patient-translations

Download the free app
NCCN.org/apps

Free copies as available
NCCN.org/free-copies
Visit the Merck Booth and Learn More About KEYTRUDA

• Approved indications
• Resources for health care professionals
• The Merck Access Program
• KEY+YOU Patient Support Program